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Summary 
The synthesis of [MX3(CO)3]2- (M = ,88Re, Re, "Tc) directly 
from the corresponding permetallates is described. Intermediates 
and byproducts have been isolated and characterized. Prelimi-
nary direct labeling studies at r.t. revealed a slow but irreversible 
incorporation of "[188Re(CO)3]+" into intact antibodies. The best 
yield was 40% after 20 h with 0.8 mg/ml of intact antibody. To 
elucidate possible coordination sites in proteins, the synthesis 
and formation of model complexes has been investigated by 
means of Ή NMR spectroscopy and X-ray structure analysis. A 
high tendency for imidazole (im) coordination has been found 
and is examplified in the model complexes [ReBr(histamine)-
(CO)3] and [Re2^-OH)2(im)2(CO)6], which structures will be 
presented. Additionally, complexation with the macrocyclic thio-
ether ligand [20-aneS6] was studied in order to establish a post-
labeling protocol with this type of chelator. The structure of 
[(20-aneS6-OH){Tc(CO)3}2]2+ will be presented. 
Introduction 
A wide variety of methods for the labeling of proteins 
and small biologically active molecules with metallic 
radionuclides have been described [1—3]. The syn-
thesis of metal complexes in general or organometallic 
complexes in particular, which are able to act as spec-
ific probes in biological systems, is one of the chal-
lenging topics in coordination chemistry directed to-
ward application [4, 5]. The key role of Afunctional 
ligands in that respect is well known and has been 
subject of several review articles discussing advan-
tages and disadvantages of the different protocols [ 6 -
8]. A broad variety of Afunctional chelators mainly 
based on open chained tetradentate N,S systems such 
as N2S2 (diamide dimercaptide) and N3S (triamide 
mercaptide) providing high thermodynamic stability 
have been prepared and successfully applied with 
!88/i86Re o r 99mTc for ^ g (p0St_ o r pre_) labeling of anti-
bodies [9—11]. Disadvantages concerning the syn-
thesis, the handling (tendency to be oxidized) and the 
availability of some of these ligands limit (sometimes) 
their general application. Since the most convenient 
labeling procedures are with radioisotopes such as 
m I n or 90Y, basically present in form of their aqua-
ions, we are interested in rhenium or technetium ana-
logues bearing, a defined number of substitution labile 
water molecules in the first coordination sphere. It is 
of further interest that ligand replacement on such a 
precursor can be performed with simple chelators, re-
sulting in complexes with high kinetic rather than in 
such of high thermodynamic stability. The latter point 
in particular makes clear that such a metal center must 
have a d6 (or d3) electronic configuration and, thus, 
its complexes belonging to the class or organometallic 
compounds of the group 7 transition elements. 
The "/ac-[M(CO)3]+" moiety, synthesis 
and properties 
Little is known about the behaviour of organometallic 
Re- or Tc-complexes in water. Among the numerous 
compounds in the +1 valency of these two elements 
only a few seem to fulfill the above-mentioned prop-
erties. In the earlier literature, the complex [NEt4]2 
[ReBr3(CO)3] has been described, but almost no fur-
ther investigations have been performed with this start-
ing material [12—14]. The reaction conditions for the 
preparation of this important synthon were optimized 
[15], but the method is not suitable for routine appli-
cation since the synthesis demands high CO pressure 
and high temperature. We therefore developed a syn-
thesis starting directly from [NBu4][M04] under at-
mospheric CO pressure. Details of the procedure are 
given in Scheme 1. 
[Re04r 
[NBU4]X, THF, C O 1atm 
RT, 1-2h, BHä'THF ~ [ReX3(CO)3] " 
macroscopic > 90%; X = CI,Br 
[188Re04]' THF,c01a tm [188ReX3(CO)3f 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
RT, 15min, BH3*THF 
no-carrler-added 30-90% 
Scheme 1. Synthesis of [MX3(CO)3]2~ under ambient con-
ditions. 
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The synthesis can be performed on the macro-
scopic as well as on the microscopic level with gener-
ator produced 188Re or with 186Re from high flux reac-
tors. However, under these conditions, two byproducts 
were detected by TLC analysis of the final organic 
reaction solution. To elucidate their nature, the reac-
tion was performed with "Tc. "Tc has been chosen 
since it allows application of the same radioanalytical 
methods as for 188/186Re and, thus, a direct instant com-
parison. Although the chemistry of the two elements 
is sometimes different, the carbonylation revealed the 
same byproducts in detectable amounts when per-
forming the reaction in the presence of [X]", but in 
quantitative yield in the absence of any [X]". The two 
compounds were identified as the mixed hydrido-
carbonyl complexes [TcH(CO)4]3 and [NBu4][Tc3H4-
(CO)12], The structure of the former byproduct has 
been elucidated by X-ray structure analysis [16]. A 
complete reaction scheme for the quantitative syn-
thesis of [MX3(CO)3]2~ is given in Scheme 2. The two 
intermediates were, after completion of the synthesis, 
transformed to [MX3(CO)3]2~ by addition of base/acid. 
Subsequently, the organic solvent was evaporated and 
then replaced by a buffer medium of choice. 
nbu4ci/Thf .99. 
co/BH,. 
T0O4]· THF/CO 
[Tc2CI3(CO)6r 
ex. BH3.THF 
PcHiCOWd + n W X W 
ex. 
NEUCI 
[TcCI3(CO)3]: 
2- H 2 0 
[Tc(OH2)3(CO)3r I 
i. NaOH H20 
1 
ii. HCl 
Scheme 2. Complete reaction scheme and characterized interme-
diates. 
As described elsewhere [17] the three [X]~ are 
readily substituted by water (or other solvent) mole-
cules, thus, the "semi aqua-ion" [M(OH2)3(CO)3]+ 
formed. This compound is water and air stable and 
fulfills the stability and coordination requirements 
pointed out above (Scheme 3). 
substitution 
labile < 
H,0 
H20' 
,co 
Re® 
CO 
CO 
h shielded; 
r substitution stable 
Scheme 3. Coordinative properties of [M(OH2)3(CO)3]+. 
Direct labeling of proteins with [188Re(OH2)3(CO)3]+ 
Direct labeling of proteins with 188Re in parallel to 
99mTc by introduction of thiol groups with a derivatiz-
CC 3 
T3 S 
- 10-· 
incubation time [h] 
Fig. 1. Direct labeling yield as a function of antibody concen-
tration: a) 800 μg b) 400 μg c) 300 μg and d) 200 μg/ml, 0.01 Μ 
phosphate buffer at pH = 7.4 and 25 °C. 
ing reagent such as iminothiolane or by reduction of 
the disulfide bridges has recently been described. It 
could be shown that incorporation takes place but is 
slow [18—20]. This corresponds to the experience, that 
rhenium reacts in general much slower than tech-
netium. In comparison, qualitative labeling experi-' 
ments were performed to investigate the direct interac-
tion of [188Re(OH2)3(CO)3]+ with intact antibodies. 
The labeling process consisted in mixing the buffer 
solution with a underivatized protein of choice. Direct 
labeling of proteins with [188Re(OH2)3(CO)3]+ fol-
lowed the same trend as observed with the reduced 
ones but with the decisive advantage that the protein 
did not have to be derivatized prior to labeling. As in 
the former case, incorporation was found to be slow. 
After purification of the labeled protein by means of 
size exclusion chromatography, stability tests were 
performed in PBS and blood serum at 37 °C. TLC 
analysis (to detect small decomposition products) and 
FPLC (trans chelation to serum proteins) revealed no 
significant loss of [188Re(OH2)3(CO)3]+ over the inves-
tigated time scale (24-48 h). The labeling yield de-
pended on the phosphate buffer concentration, which 
is reasonable taking the weak interaction of the 
[H2P04]"/[HP04]2~ anions with the cationic carbonyl 
complex into account. Furthermore, the labeling yield 
was a function of protein concentration. The highest 
yield in the investigated range was about 40% incorpo-
ration after 20 h at r.t. (Fig. 1). The good linearity 
(yield vs. protein concentration) supports a pseudo 
first-order kinetic model. Also in agreement with this 
model is the fact that the labeling yield was found to 
depend only slightly on the absolute amount of radio-
activity (Fig. 2). Increasing the amount of 188Re left 
the yield almost untouched but increased the specific 
activity of the radioimmunoconjugate by the corre-
sponding factor. In the investigated range the highest 
specific activity achieved was about 130 MBq/mg of 
protein. Biological in vitro activity was verified to be 
retained in three different experiments with the method 
introduced by Lindmo et al. [21]. 
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Fig. 2. Direct labeling yield as a function of amount of 188Re. 
It can be concluded from these results, that 
direct labeling of underivatized antibodies with 
[188Re(OH2)3(CO)3]+, providing a [188Re(protein)-
(OH2)2(CO)3]+ complex of high kinetic stability is 
possible. The labeling rates at r.t. are slow but can be 
increased probably by factors by increasing tempera-
ture and protein concentrations, according to the ob-
served qualitative kinetic behaviour. In terms of con-
venience, the protocol is easier than a prelabeling pro-
cedure with multidentate ligands, but the synthesis of 
the precursor complex [188Re(OH2)3(CO)3]+ has to be 
adapted to the requirements for a routine protocol. 
It is not yet clear if the labeling takes place at a 
specific side chain of the amino acids in the protein or 
if the labeling is nonspecific. To study the interaction 
with various groups, several model complexes have 
been prepared and their properties studied. Of most 
interest is in particular the imidazole function (in his-
tidine) or the thioether function (in methionine), al-
though the concentration of the former one is low ( 4 -
20, depending on the protein) while the latter is usu-
ally located in lipophilic cavities of proteins and not 
readily available for complexation. 
Model complexes with imidazole and histamine 
These two ligands were chosen since the imidazole 
(im) group is part of histidine and is thus present in 
the hydrophilic part of proteins. Imidazole represents 
a monodentate ligand, whereas histamine is bidentate 
and can provide two coordinating sites, an aromatic 
and an aliphatic amine, thus, allows the elucidation 
of the corresponding preferences. Complexation with 
different metal/ligand ratios has been studied in water 
and in methanol. Methanol has been chosen to exclude 
pH equilibria and to answer the question to what ex-
tend imidazole alone is able to coordinate to the 
[M(CO)3]+ moiety. To analyse and characterize poten-
tial intermediates, the reaction was followed by 
Ή NMR spectroscopy. This method allowed the 
[Re(sol)3(CO)3]+ [Re(sol)2(im)CO)3]+ 
| + im 
[ReBr(im)2(CO)3] J Ü - [Re(sol)(im)2(CO)3f 
Scheme 4. Stepwise coordination of im to the [Re(HOCH3)3-
(CO)3r. 
characterization and isolation of the intermediates de-
scribed in the reaction pathway of Scheme 4. 
Substitution of a first im to [Re(HOCH3)3(CO)3]+ 
occurred with a half life time of about 15 min, coordi-
nation of a second im to [Re(Im)(HOCH3)2(CO)3]+, 
which takes place conceitedly to the first im coordi-
nation, with a half life time of about 45 min. The prod-
uct [ReX(Im)2(CO)3] was finally formed by substi-
tution of the last [HOCH3] by [X]". This was con-
firmed by comparing the Ή NMR spectra of the reac-
tion mixture with those of the analogous compound 
isolated and structurally characterized. In the presence 
of [X]", coordination of a third im is not observed. 
Only precipitation of [X]" with [Ag]+ salts and sub-
sequent reaction with 3 eq of im allowed the isolation 
of [Re(im)3(CO)3]+. This threefold coordinated species 
is obviously not relevant for consideration in biologi-
cal processes, since coordination of a halide instead of 
a third im is prefered for reasons of charge compen-
sation. The situation is slightly different in aqueous 
systems. At pH values below 6, the behaviour was 
found to be similar in that a monosubstituted complex 
is formed on a comparable time scale as in methanol. 
At physiological pH (pH > 6) however, the com-
plexation of one im ligand per rhenium went along 
with [OH-] substitution. Two [OH]- bridge two rhe-
nium centers to form finally [Re2(im)2^-OH)2(CO)6]. 
An ORTEP presentation of the molecule is depicted in 
Fig. 3. Acidifying such a solution to pH < 1 did not 
split the im from the rhenium but resulted only in OH-
• 5 0 0 μ ρ A K - 4 7 
I I 2 0 0 μ ρ A K - 4 7 
1 2 
relative initial activity 
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Fig. 4. ORTEP presentation of [ReBr(hist)(CO)3]. 
bridge cleaving and, thus, in the formation of 
[Re(im)(OH2)2(CO)3]+ demonstrating the kinetic inert-
ness of the coordinated im group. 
The extension to a bidentate ligand was performed 
with histamine (hist), which can provide one im ligand 
and one primary amine group as coordinating sites. 
Ligand exchange reactions in methanol revealed the 
same features as for imidazole alone. Slow initial co-
ordination of one histamine was followed by incorpo-
ration of one [X]" to yield the final product [Re-
Br(hist)(CO)3] the structure of which was elucidated. 
An ORTEP presentation of the complex molecule is 
given in Fig. 4. The coordination of imidazole part and 
the primary amine group in histamine occured con-
ceitedly as shown by Ή NMR investigations. The 
combination of aromatic and aliphatic amines, as pre-
sent in histamine, does not occur in proteins but in 
histidine itself (with one carbon less in the chelate 
ring). Since histamine, which forms highly stable com-
plexes with [Re(OH2)3(CO)3]+, is present as a chelat-
ing sub-unit in histidine, the uncoordinated carboxylic 
acid group in this amino acid could be used as a link-
ing group to proteins. Therefore histidine might act as 
an interesting bifunctional ligand for the labeling of 
small molecules and proteins. 
It can be concluded from the observed behaviour, 
that imidazole plays an important role in the direct 
labeling of proteins due to its high tendency to coordi-
nate to [Re(OH2)3(CO)3]+. The rate of coordination 
followed roughly that one observed with proteins and, 
once coordinated, imidazole exhibited a high kinetic 
stability, which is in coincidence with the behaviour 
observed for labeled antibodies. 
Substitution behaviour 
with the bifunctional macrocyclic thio crown 
[20-aneS6-C>H] 
Beside the possibility of direct protein labeling, 
[M(OH2)3(CO)3]+ might also be subject of a postlabe-
ling procedure. Postlabeling is the prefered method, 
since labeling yield depends only on ligand exchange 
rate and equilibrium with a convenient precursor com-
plex. Consequently, yields are usually quantitative, in 
contrast to those for a prelabeling procedure. The prin-
ciple of postlabeling is routine for "mTc but is hardly 
done for 188Re in the +V valency due to the lack of 
an easily accessible and sufficiently stable precursor. 
[188Re(OH2)3(CO)3]+ might play this role. Proteins are 
derivatized with particular ligands known for strong 
interaction with [,88Re(OH2)3(CO)3]+. Thio crowns are 
such ligand systems and for the labeling process they 
have only to be mixed with the [188Re(OH2)3(CO)3]+ 
complex. 
To model this reaction, we have selected the 
[9-aneS3] and [20-aneS6-C)H] thio crowns, the latter 
one resulting from our interest in u lAg for applica-
tion in radioimmunotherapy [22]. Transchelation of 
[M(sol)3(CO)3]+ with [9-aneS3] in organic solvents 
occured within 20—30 min and the complex [(9-
aneS3)M(CO)3]+ was formed quantitatively after this 
short period of time. [20-aneS6-C)H] reacted on a com-
parable rate and, consecutively, two "[M(CO)3]+" 
fragments coordinated to yield finally the complex 
[(20-aneS6-OH){Tc(CO)3}2]2+. An ORTEP represen-
tation of the molecule cation is given in Fig. 5. The 
twofold coordination per ligand offers the possibility 
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of increasing the specific activity of a radioimmuno-
conjugate by a factor of two without increasing the 
number of derivatized sites. Reaction with m R e is 
slower and demanded a few hours for completion. If 
the prefered coordination site is the macrocycle or if 
considerable amounts of 188Re is still directly bound to 
the protein, is under investigation. 
Conclusion 
The organometallic 188Re precursor complex [188ReX3-
(CO)3]2~ can be prepared directly from trace amounts 
of [188Re04]~ in organic solvents in good yield and 
under similar conditions also with macroscopic 
amounts of Re or Tc. The "aqua-ion" [M(OH2)3(CO)3]+, 
resulting from the dissolution of [188ReX3(CO)3]2~ in 
water, is stable and provides three potential coordi-
nation sites. Substitution with different ligands showed 
high kinetic stability of the resulting complexes, in 
particular when these ligands beared an imidazole resi-
due. Therefore, the histidine side chains seem to be 
responsible for direct labeling of intact antibodies, 
which occured slowly but irreversibly to a maximum 
of 40% incorporation with retention of biological ac-
tivity. [188Re(OH2)3(CO)3]+ reacts with bifunctional li-
gands and can chemically be treated like an aqua-ion. 
Especially in the case of 188Re, postlabeling protocols 
can thus be envisaged with the appropriate ligands at-
tached to a protein. If direct labeling occurs site spe-
cific or unspecific is under investigation. 
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Summary 
In the direct labeling of antibodies with Re-186, 188, the lower 
redox potential of Re04 than TcOj requires the addition of ex-
cess SnCl2 and a medium-chelating agent for stabilizing the ex-
cess of SnCl2 in solution. Through extensive tests, sodium glu-
coheptonate (GH) was chosen as an excellent stabilizer for SnCl2 
and also the reduced Re(V) from a variety of chelators, such 
as citrate, cyclodextrin, tartrate, inositol, glucose, glycine, etc. 
ReOj solution was then quantitatively reduced for 2 h with new-
ly prepared SnCl2(GH) solution. Then, we directly incorporated 
the reduced Re to the antibodies IgG modified with 135 fold of 
NaHSOj and 3500 fold of 2-ME, and more than 90% of specific 
binding was yielded in 100—150 min at room temperature. TLC 
analysis indicated that less than 5% of activity was in the colloid 
form. Radiolabeled antibodies IgG were stable to the challenging 
of 700 fold of DTPA, and also showed fine in vivo stability. 
Introduction 
Re-186 has been regarded as an ideal radionuclide for 
radioimmunotherapy due to its appropriate half-life of 
90 h and β emission of 1.07 MeV. Moreover, the γ 
emission of 137 keV that allows in vitro imaging while 
in therapy is an additional bonus [1], Tumor specific 
monoclonal antibodies (MoAbs) are currently receiv-
ing much attention as a carrier to deliver radionuclides 
onto malignant tumors. 
Many attempts have been made to label MoAbs 
with Re-186 directly or indirectly via bifunctional 
chelators [2—5]. Some application of the indirect 
labeling protocol in clinical trials even showed prom-
ise in the treatment of cancers [6—8]. However, since 
the indirect labeling protocol involving multisteps of 
synthesis, reduction, conjugation, labeling and post-
purification is very inconvenient for routine prep-
aration, hence, increasing efforts are paid to the direct 
labeling method. 
In previous studies, the employment of SnCl2, 
Na2S204 or H3P02 as the reducant of ReO^ gave very 
low and varying labeling yields [4], Though the ad-
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
dition of a transferring agent of citrate or tartrate drove 
the reduction of ReO^ more complete, the strong che-
lating ability of citrate or tartrate prevents the trans-
chelation of reduced Re to protein. Griffiths and co-
workers used a medium ligand as the transchelation 
agent of Re(V) and also a stabilizer of large amount 
of SnCl2. Rapid labeling of MoAbs at high yields was 
therefore achieved [9]. Unfortunately, no detail about 
this ligand was given. 
In this paper, sodium glucoheptonate was chosen 
as a stabilizer of Sn2+ and a transchelation agent of 
Re(V). The complete and rapid reduction of carrier-
containing 186Re04 was achieved, and then the direct 
labeling of antibodies IgG with the reduced 186Re was 
made. 
Experimental 
Human polyclonal IgG was purchased from Shanghai 
Institute of Biological Products, China. 186Re produced 
by the reaction 185Re(n,y)186Re in reactor was a gift 
from Institute of Isotopes of China Atomic Energy 
Academy. 186Re was in a form of H186Re04 with a 
specific activity of 1 - lOX 108 Bq. Sodium glucohep-
tonate (GH) was prepared as previously reported [10]. 
All other reagents were of reagent grade. 
Testing of stabil izer of Sn2 + 
Six ligand solutions of glucose (200 mg/ml), GH(200 
mg/ml), starch (saturated), inositol (200 mg/ml), cy-
clodextrin (saturated) and glycine (200 mg/ml) were 
tested. 
When at pH 4.0 of acetic buffer solution (ABS), 
SnCl2 stably existed in all six ligand solutions, while 
at pH 5.9, hydrolysis of Sn2+ was not observed only 
in GH and glycine solution. However, pH raised up to 
6.2, only GH can effectively keep Sn2+ in solution. 
Therefore, GH was chosen as a suitable ligand. 
Radiolabel ing of antibodies IgG 
1. Reduction of,a6Re04 
SnCl2 solution was freshly prepared by dissolving 
100 mg of SnCl2 · 2 H20 in 10 μΐ of concentrated HCl 
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Table 1. The Rf values of different radiolabels 
Radiolabel Rf values 
Paper 
chromatography 
ITLC 
,86Re-IgG 0.0 1. 0 
,86Re-Sn Colloid 0.0 0. 0 
l86Re-GH 1.0 1. 0 
l86ReC>4 0.8 1. 0 
Table 2. In vitro stability of 186Re-IgG at 37 °C (%) 
Reductants Challenge Challenging time (hr) 
agent 
2 4 6 18 24 
2-ME No challgenge 87 89 92 91 94 
agent 
1:700 DTPA 87 88 90 90 89 
1:1000 EDTA 86 87 89 88 88 
1:200 MAG3* 56 45 41 40 38 
NaHS03 No challenge 89 88 95 94 95 
agent 
1:700 DTPA 89 90 92 93 91 
1:1000 EDTA 87 80 80 80 79 
1:200 MAG3* 54 39 40 34 36 
*MAG3: Mercapto-Acetyl-Glycyl-Glycyl-Glycine. 
and 2 ml of H20, while 400 mg of GH was dissolved 
in 1 ml of 0.2 Ν ABS (pH 5.0), and then heated in 
boiling water to obtain a clear GH solution. The GH 
and SnCl2 solutions mentioned above were mixed in a 
volume ratio of 5:4 to prepare Sn(GH) solution. The 
reduced 186Re solution was obtained by mixing 2 ml 
of H186Re04 with 1 ml of Sn(GH) solution and then 
shaking for 2 h. 
2. Reduction of antibodies IgG 
The antibodies were reduced with 2-mercaptoethanol 
(2-ME) and NaHS03 respectively. 
For 2-ME method, IgG solution (5 mg/ml in pH 
5.0, 0.1 Ν ABS) was reduced with 3500 molar excess 
of 2-ME for 30 min. This mixture was purified from 
excess 2-ME through a Sephadex G-50 column. The 
labeling was conducted by mixing 100 μΐ of elute with 
10 μΐ of 0.05 Μ ascorbic acid, followed by incubation 
with 50 μΐ of reduced Re solution for 2 h. 
For NaHS03 method, 200 μΐ of IgG solution was 
reduced with 30 μΐ of 0.03 Μ NaHS03 solution for 
40 min prior to incubation with 100 μΐ of reduced Re 
solution for 2 h. 
3. Quality control 
The labeling yields of 186Re-IgG was determined by 
paper chromatography developed in 0.9% NaCl. The 
colloid formation in radiolabel was detected by instant 
thin-layer chromatography (ITLC). The Rf values of 
the involved species in ITLC and Paper Chromato-
graph tests are listed in Table 1. 
In vitro s tab i l i ty of r ad io labe l 
The stability of radiolabel was assessed by challenging 
the labeled IgG with 700 molar excess of DTPA, 1000 
molar of EDTA and 200 molar of MAG3 at 37 °C 
respectively. After a time interval, the radiochemical 
purity was analyzed. 
Animal d i s t r ibu t ion 
Normal mouse of 20—25 g and 4 wk old, was injected 
with 100 μΐ of 186Re-IgG solution through abdominal 
cavity. At several hours of postinjection, three mice 
were scarified, and the ID%/g in organs were deter-
mined by counting the activity of weighed organs in 
y-well scintillation counter. 
Results and discussion 
For 2-ME method, labeling of IgG was accomplished 
for 150 min to give reproducible yields of 90%, and 
less than 5% of colloid formation was assayed by 
ITLC. For the method of NaHS03, 2.7 Χ ΙΟ"3 Μ of 
NaHS03 was used to reduce IgG in 40 min. The re-
duced IgG was then labeled with reduced 186Re in 1 h, 
and the labeling yields ranged from 93% to 95%, but 
the activity bound to colloid was only 7.1%. 
Table 1 lists the results of challenging 186Re-IgG 
labeled with method of 2-ME and NaHS03. It shows 
that the radiolabels prepared by both method of 2-ME 
and NaHS03 are considerably stable. However, in con-
trast to 2-ME method, the NaHS03 method is simple 
and free of further purification from 2-ME, and even 
gives a higher labeling yield of 95%. 
The biodistribution of 186Re-IgG labeled with 2-
ME and NaHS03 method is plotted in Fig. 1. The dis-
tribution of 186Re-IgG significantly differed from that 
of free 186Re04. The activity of 16ReC>4 was found to 
accumulate mainly in thyroid and stomach other than 
in kidneys and liver, while the ID%/g of the radiolabel 
186Re-IgG in liver and kidneys are much higher than 
that of 186Re04. Though the liver and kidney clearance 
appeared to be a little quick, it still fell in the range 
observed by other researchers [3]. 
For the past decade, approaches have been well 
established to label MoAbs directly with "mTc(V) 
[11], which chemical property is similar to that of Re. 
However, the redox potential for the reduction of 
ReO; is about 220 mV lower than that for TcOi. Re 
complexes are more thermodynamically stable against 
reduction in their higher oxidation state than the analo-
gous Tc complexes [12]. Therefore, some stronger 
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Fig. 1. Biodistribution of 186Re-IgG in normal mice at 24 h post injection. 
reduction conditions were usually used to reduce 
186Re04, such as very acidic buffer pH„ lengthening 
the reducing time, adding large excess of SnCl2, etc. 
Generally, only the addition of large amount of SnCl2 
was widely accepted. Nevertheless, large excess of 
SnCl2 hydrolyzes at pH 4 - 1 0 [13]. Though ReO; can 
be firstly reduced at pH 1—2, the reduced Re will be 
reoxidized to perrhenate by ambient 0 2 while pH up 
to 5 (12). A stabilizer to keep SnCl2 stable in pH > 4 
buffer was thus required. 
GH can stabilize SnCl2 pH > 4.0, and even at near 
neutral pH. Also, the labeling time of 1—2 hr in our 
study indicated that GH did not prevent the transchel-
ation of the reduced Re to protein. In our recent inves-
tigation, the generator-produced carrier-free 188Re was 
readily reduced with stannous citrate and tartrate, 
which was in good agreement to the studies of Grif-
fiths and Winnard [9, 14]. While labeling with carrier-
containing 186Re, the presence of large amount of 
carrier 185Re necessitates the addition of much more 
excess of SnCl2 than that needed in case of carrier-free 
188Re. Accordingly, large amount of strong stabilizer, 
such as citrate or tartrate, should be added to stabilize 
Sn2+, but it will prevent the subsequent transchelation 
of reduced Re(V) to protein. 
We have found that GH, a transchelation agent and 
a stabilizer with medium chelating ability, could suc-
cessfully be applied for direct labeling of antibodies 
IgG with carrier-containing 186Re. 
In summary, sodium glucoheptonate serving as an 
excellent stabilizer of Sn2+ at near neutral pH and the 
transchelation agent, we have labeled antibodies IgG 
with carrier containing 186Re, which was reduced with 
2-ME and NaHS03 respectively. The labeling yields 
were more than 90%, and both challenging test and 
biodistribution results demonstrated that the radiolabel 
had good in vivo and in vitro stability. 
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Summary 
The promising application of Mercapto-acetyl-glycycl-glycyl-
glycine (MAG3) in the radiolabeling of monoclonal antibodies 
with Re has attracted us to synthesize four analogs of MAG3 as 
bifunctional chelating agents (BFCAs) in improved convenient 
routes. All the four compounds of Bz-MAG2-EACA, Bz-MAG-
(L)-A-EACA, Bz-MA-(L)-A-G-EACA, Bz-MA-(L)-A-(L)-A-
EACA, which own a long spacer of e-amino caproic acid 
(-EACA), have been characterized with E.A., IR,MS, and 
'HNMR. Bz-MAG2-EACA was used as BFCA to label anti-
bodies with Re-186 according to a well-established labeling pro-
toco. Optimization was conducted to achieve 45—48% conjugat-
ing yields, and the resulted in good in vivo and in vitro stability 
of the radiolabel. 
Introduction 
Due to the excellent nuclear properties of 186Re for 
radioimmunotherapy, increased efforts have been 
made to radiolabel tumor-specific monoclonal anti-
bodies (MoAbs) with 186Re via bifunctional chelating 
agents (BFCAs), such as DTPA [1], triaminedithiol li-
gands [2], MAG3 [3] or the others [4, 5]. 
As chelating agent, MAG3 along with its analogs 
has received much more attention than others because 
of the high in vivo stability of MAG3-metal complexes. 
However, when the MAG3 analogs with terminal ami-
no acid of two or three-carbon main chain were used 
for labeling of MoAbs, the formation of an intermedi-
ate of five or six-membered ring will stimulate the hy-
drolysis of the active ester, decreasing the conjugation 
yield [6]. MAGa-y-aminobutyric acid (MAG2-GABA) 
owning a longer carbon chain in the terminal aminoac-
id was better to be employed as BFCA for the radio-
labeling of MoAbs. Furthermore, the application of 
this label in clinical treatment has shown promise for 
the therapy of a variety of cancers [ 7 - 9 ] . Generally, a 
chain length of five or six carbon was thought to be 
most favorable [1]. 
We have synthesized four new MAG3 analogs, 
which own ε-amino caproic acid (-EACA) as a termi-
nal aminoacid by a convenient synthetic method. The 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
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radiolabeling of antibodies with 186Re via the synthe-
sized Bz-MAG2-EACA and the bioevaluation of radio-
label in normal mice were also reported. 
The abbreviations described in this paper are as 
following: DTPA Diethylene-triamine-pentaacetic 
acid, Bz benzoyl, THF tetrahydrofuran, TFA trifluo-
roacetic acid, A alanine, G glycine, NHS N-hydroxy-
succinimide, DCC dicyclohexyl carbiimide, EDC 1-
ethyl-3-(3'-dimethylaminopropyl)-carbiimide, t-BOC 
t-butyloxycarbonyl, TFP tetrafluorophenol, EACA ε-
amino caproic acid. 
Experimental 
Human polyclonal IgG was purchased from Shanghai 
Institute of Biological Products, China. The carrier-
containing 186Re in the form of H1 8 6Re04 with a spec-
ific activity of 1 —10 Χ108 Bq was a gift from Isotope 
Institute of China Academy of Atomic Energy. 
C h e m i c a l s y n t h e s i s 
The MAG3 analogs were synthesized according to the 
synthetic routes shown in Scheme 1. 
When R, R ' = H , the final product is benzoyl-mercap-
to-acetyl-glycycl-glycycl-e-amino caproic acid (Bz-
MAG2-EACA). Besides MAG2-EACA, other three 
new MAG3 analogs with a terminal caproic acid were 
synthesized. 
L a b e l i n g of a n t i b o d i e s I g G 
IgG was labeled with carrier-added 186Re via Bz-
MAG2-EACA by Visser's protocol [3]: 
1. 186Re04 was reduced in 2 h by twice of Sn-glu-
coheptonate (GH) solution which was freshly pre-
pared by mixing SnCl2 (50 mg/ml) solution and GH 
(400 mg/ml) solution in 5 :4 volume ratio. 
2. Meanwhile, 5 mg of Bz-MAG2-EACA was dis-
solved in 1 ml of 0.2 Ν NaOH. The deportation of 
benzoyl group was accomplished by incubation in 
boiling water for 5 min. The pH of solution was 
then adjusted to 9.0 with 2 Ν HCl. 
3. 50 μΐ of solution obtained above was mixed with 
80 μΐ of reduced Re solution prepared in step 1, and 
then vortexing for 30 min. 
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Scheme 1. Synthesis of MAG3 analogs by active ester approach. 
4. To this mixture, 30 μΐ of TFP (100 mg/ml) in 
CH3CN/H20 (9:1) solution and 2 mg of EDC solid 
were added. Then, additional 15 μΐ of CH3CN/H20 
solution was added to keep the solution clear. The 
mixture was allowed to stand for 30 min. 
5. The solution was heated under a stream of N2 at 
50 °C to dryness, and added with 200 μΐ solution of 
IgG (5 mg/ml) in 0.2 Ν carbonate buffer solution of 
pH 10. The conjugation was performed by incuba-
tion of 2 h. 
Results and discussion 
Through the outlined synthesis route, the overall yields 
of four new MAG3 analogs amounted to 15.4—23.5%. 
In our synthetic routes, at one side Bz-mercaptoacetyl 
amino acid was synthesized by reaction of succinimid-
yl Bz-mercaptoacetate with an aminoacid component, 
while at another side dipeptide was synthesized by an-
other reaction of N-protected aminoacid with ε-amino 
caproic acid. Therefore, the problems of low solubility 
of the intermediate and the inconvenient availability 
of dipeptide and tripeptide were solved. Furthermore, 
a variety of MAG3 analogs with proper components 
can be feasibly synthesized following this approach. 
In metal complexes of MAG3 analogs, the car-
boxyl group which does not participate in the com-
plexation can react with the lysine residues of anti-
bodies, and can therefore be used as BFCAs for radio-
labeling of MoAbs for radioimmunotherapy. The in-
direct radio-labeling of MoAbs with BFCAs could 
generally be made by two ways: 1) to label the BFCAs 
with radionuclide first, and then conjugate antibody 
with the radiolabeled chelator, or 2) conjugate the 
BFCAs to antibody prior to the radiolabelling of modi-
fied antibody. In the labeling of MoAbs with Bz-
MAG3 analogs as BFCAs, following the second route, 
the severe condition will considerably damage the im-
munoreactivity of MoAbs, because the deprotection of 
benzoyl group from the MAG3 analogs in the labeling 
procedure was carried out in very basic pH environ-
ment and at high temperature, such as in boiling water. 
Therefore, the procedure of labeling BFCAs prior to 
conjugating with MoAbs was adopted in this study. 
With our labeling protocol, the conjugation of 186Re-
MAG2-EACA with the protein was accomplished to 
yield a very stable label with a reproducible yield of 
48%. 
In the challenging test, after 24 h of incubation in 
the presence of 500 fold of DTPA at 37 °C, there was 
still 92.3% of activity bound to protein, showing that 
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Scheme 2. Structures of the synthesized MAG3 analogs. 
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Fig. 1. Biodistribution of ,86Re-MAG2-EACA-IgG in normal mice. 
186Re-MAG2-EACA-IgG was very stable in vitro. 
Moreover, the biodistribution result of the label shown 
in Fig. 1 suggested its satisfactory in vivo stability. In 
contrast to the biodistribution of free 186ReC>4, only a 
minor activity of the label accumulated in thyroid and 
stomach, but a major activity in kidney and liver. 
In conclusion, we have synthesized four new 
MAG3 analogs which own a terminal aminoacid with 
a longer carbon chain-ε-caproic acid. All the four 
compounds were characterized with IR, Elemental 
Analysis, MS and 'HNMR, and the overall yields of 
synthesis amounted to 15.4—23.5%. Using Bz-MAG2-
112 Zhihong Zhu, Yonghui Wu and Yuanfang Liu 
EACA as BFCA, human polyclonal IgG was labeled 
with 186Re. The labeling yield was up to 4 5 - 4 8 % . 
Both the challenging and biodistribution tests indicate 
that the label has good in vitro and in vivo stability. 
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Summary 
,88Re-HEDP has been prepared from lyophilized kits with 188Re 
from the alumina 188W/188Re generator for evaluation for poten-
tial, cost-effective pain relief for patients with bone metastases. 
SnCl2 · 2 H20 was used for reduction with varying amounts of 
Re carrier (0—300 μg per kit) and TLC was used for quality 
control (QC). An inert atmosphere and carrier were critical fac-
tors to achieve high radiolabeling yields in reasonable time 
(<10 min) and preparations were stable for at least 24 h. Slow 
reaction kinetics were found without carrier addition (i.e. 90% at 
6 h) with low decomposition followed during 200 h under inert 
conditions. In vivo studies conducted in mice, rats and rabbits 
demonstrated rapid bone uptake, blood clearance, and high renal 
excretion with negligible liver and thyroid activity. Good images 
were obtained using the 155 keV gamma photon without ß~ 
shielding using a medium energy-high resolution (MEHR) col-
limator at a distance of 2 cm. These encouraging results will be 
expanded to dosimetric studies and clinical trials. 
Introduction 
Since the chemistry of Re closely resembles tech-
netium chemistry [1-3], the "mTc-HEDP diagnostic 
agent which selectively accumulates in abnormal or 
cancerous tissue was used as a model for development 
of the Re analog. Rhenium radioisotopes (186Re, 188Re) 
have attractive properties for therapy [4—8], 188Re is 
obtained from a tungsten-188/rhenium-188 (188W/ 
188Re), radionuclide generator system, representing an 
advantage for availability at radiopharmacy laboratory 
by daily elution [9—11]. In addition, 188Re emits high 
energy beta particles with an average energy of 
769 keV, and the emission of the 155 keV gamma pho-
ton which permits the biodistribution evaluation in 
vivo of 188Re-labeled agents with a gamma camera. 
The feasibility of using 188Re-HEDP in bone metasta-
sis therapy was evaluated in our studies. We describe 
formulation studies, kit preparation, radiolabeling, 
quality control and in vitro stability studies of the ra-
diolabeled compound, based upon the literature on 
commercially available 186Re-HEDP and conditions 
for gamma camera imaging were also evaluated. 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
Experimental 
Reagents and materials 
188Re-perrhenate was obtained by elution with 20 mL 
0.9% saline from 188W/188Re generator [9] fabricated 
at the Oak Ridge National Laboratory (ORNL), Oak 
Ridge, Tennessee, that had previously been eluted 
2 days earlier. For kit preparation, 1-hydroxyethylid-
ene diphosphonic acid (Fluka AG, purity >97%), 
gentisic acid (Aldrich, purity = 99%), tin(II) chloride 
dihydrate (Baker, purity = 100%), potassium perrhen-
ate carrier (Aldrich, purity = 99%) and high purity 
nitrogen gas (99.99%) were used. All other inorganic 
chemicals were of reagent grade. 
Formulat ion studies and procedure 
for kit preparat ion 
The kits were prepared by the following technique: 
100 mg of HEDP and 30 mg of gentisic acid were dis-
solved in 9.7 mL of water, 37 mg of SnCl2 · 2 H20 was 
dissolved in conc. HCl and the two reagents were then 
combined. We studied the influence of potassium per-
rhenate carrier. For these studies, 10 mg of potassium 
perrhenate was dissolved in 1 mL of distilled water 
and 10, 15, 30, 100, 150 or 300 pL of this solution 
was added for the kit formulation mixture. This mix-
ture was then diluted to 10 mL and dispensed into 
vials of 1 mL each. The vials were filled with nitrogen 
to produce a protecting inert gas atmosphere and 
stored at 2-8°C. The pH of the solutions was about 
1.0-1.5. 
For preparation of the lyophilized kits, each solu-
tion, under sterile conditions (laminar flow hood) was 
taken up into a 10 mL one way syringe, dispensed into 
sterile vials via a sterile filter and lyophilized for 
24 hours. Kits were stored at 2 -8°C. 780 mg of 
sodium acetate trihydrate was dissolved in 20.0 mL 
distilled water and was taken up into a 20 mL one way 
syringe and dispensed into sterile vials of 2 mL via a 
sterile filter. To ensure sterility of lyophilized kits, 5 
vials were randomly separated, and evaluated. 
Labeling procedure and quali ty control 
A labeling kit, prepared as described above, was 
mixed with 1.0 mL of the generator eluate (5—20 mCi, 
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Fig. 1. Effects of carrier perrhenate on the radiolabeling ef-
ficiency and stability of the rhenium-188-HEDP complex for 
24 hours. 
CRC 6 Radioisotope Dose Calibrator). The solution 
was heated at 100°C for 10 minutes. After cooling to 
about room temperature, in order to achieve final pH 
in a range of 5—6, sodium acetate was added. The pH 
was controlled by pH indicator strips. Visual inspec-
tion corroborated the expected yellow color and ab-
sence of any particles. 
Free perrhenate was evaluated by using chroma-
tography paper (Whatman 1M) as the stationary phase 
and acetone as the mobile phase. Rhenium oxide 
(Re02) or colloids and Re-188-HEDP remained at the 
origin whereas Re-188-perrhenate moved with the sol-
vent front. Rhenium oxide or colloids were evaluated 
using chromatography paper (Whatman 3MM) and 
HEDP 0.01 Μ in 0.9% NaCl solution as mobile phase. 
While the oxide and colloids remained at the origin, 
Re-188-HEDP and Re-188-perrhenate moved with the 
solvent front. After development, the strips were cut 
into 1 cm segments, the activity measured and the ra-
diochemical purity calculated. In order to determine 
the kinetic formation of the radiolabeled compound at 
room temperature obtained from the different formu-
lations, chromatographic controls were evaluated. 
In vitro stability of the 188Re-HEDP was studied in 
all formulations over 24 hour period and in the low 
range, from 0 to 30 μg carrier per labeling, the controls 
were continued for up to 200 hours. 
Studies in labora tory animals 
Mice (25—30 g weight) were injected with 0.05— 
0.1 mL of 188Re-HEDP solution with 100-800 μ Ο 
Table 1. 188Re-HEDP biodistribution in mice expressed as % 
remaining ID/organ (mean + / - 1 s.d.; n = 4) 
Tissue 2 hours 24 hours 
blood 2.9 ±1.2 1.0±1.1 
liver 2.3±1.1 0.8±0.2 
lungs 0.49 ±0.14 0.15±0.26 
kidney 2.4±0.9 1.0±0.3 
thyroid 0.37±0.11 0.29±0.09 
muscle 7.9±2.2 0.02±0.01 
bone 65.5±7.6 79.8±3.1 
(RQ.P. >98%) through a lateral tail vein. Animals 
were sacrificed at 2 and 24 hours, and samples of 
blood, muscle and bone were collected in preweighed 
containers and other organs were removed intact. Or-
gans and tissue samples were assayed for radioactivity 
[Nal(Tl) 3" X 3", Ortec] and the organ uptake values 
then calculated as a percentage of the total remaining 
dose in organ at preset time. Eight-hour fasted rats 
(270-300 g weight) were injected with 0.1-0.2 mL 
(300—900 μ0 ) , housed in metabolic cage for collec-
tion of urine and gamma camera images were done at 
2 and 24 hours (Sopha Sophycammera DSK, 93 PMT, 
SPECT). Rats were anesthetized with 40 mg/k i/p 
pentobarbital for image acquisition. For each time 
point, an animal was sacrificed and organs and tissue 
samples were assayed as were previously described for 
mice. The radioactivity in whole blood, bone and 
muscle were calculated as 7%, 10% and 43% of the 
total animal weight (mice or rat). 
Biodistribution of the labeled compound in rabbits 
(1.0—1.2 mCi i .V.) , which were anesthetized with 
-*"30iig 
— 15A«g 
-*-•\0μg 
— Ojug 
0 50 100 150 200 250 
TIME (h) 
Fig. 2. Effects of carrier perrhenate on the stability of the rhe-
nium· 188-labeled HEDP complex. 
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Fig. 3. Effects of low energy high resolution (LEHR), medium energy (ME), and medium energy high resolution (MEHR) collimators 
at a 2 cm distance on the image quality obtained with a Sopha Sohpygamma DSK Camera 24 hours after intravenous administration 
of rhenium-188-HEDP to rabbits. 
20 mg/k 17m ketamine and 1.5 mg/k s/c phenotiazine, 
was also investigated by gamma camera acquisition at 
2 and 24 hours. 
Results 
Figs. 1 and 2 illustrate the effect of carrier on kinetic 
formation of the radiolabeled compound and in vitro 
stability, where the kit formulation with 300 μg of po-
tassium perrhenate conducted to a radiochemical pu-
rity of 99.5±0.5 (mean ± 1 s.d.; η = 6) immediately 
after labeling, without modification during 24 hours. 
For this reason, this composition was selected for pre-
paring lyophilized kits of HEDP and carrying out ani-
mals studies. Mice biodistribution results are shown in 
Table 1. Excreted urine, determined in these biodistri-
butions, reached a mean of 81.6% ± 1.7 (1 s.d.) in the 
first 2 hours. The best acquisition conditions for gam-
ma camera imaging were determined using a medium 
energy high resolution (MEHR) collimator without ß~ 
shielding at a distance of 2 cm between the animal and 
collimator. Fig. 3 illustrates different rabbit images in 
which both the distance from the collimator and the 
• RATA 1- 1 J. -07-95 
RftT 1 HIGH ENERGY COilMftTOR 
Fig. 4. Rat image obtained with a Sohpygamma DSX Camera 
using a MEHR collimator obtained 24 hours after intravenous 
administration of rhenium-188-HEDP. 
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Fig. 5. Effects of gamma photon energy window setting and β shielding on the image quality using a MEHR collimator at a 2 cm 
distance with a Sopha Sohpygamma DSK Camera 24 hours after intravenous administration of rhenium-188-HEDP to rabbits. 
type of collimator were varied. Fig. 4 shows a rat im-
age obtained at 24 hours after injection and Fig. 5 
shows a series of rabbit images obtained with the 
MEHR collimator under various imaging conditions 
with and without ß~ shielding. Seventy percent of the 
administrated dose was observed in rat urinary ex-
cretion at 24 hours, where 75% of the retained activity 
was present in bone. 
Discussion and conclusions 
Selected kit formulation of HEDP for labeling with Re 
showed that 188Re-HEDP exhibits good physicochem-
ical properties. Inert atmosphere and carrier were both 
critical to achieve high labeling yields (radiochemical 
purity >99%) in a reasonable time period. In vitro 
stability studies showed that the radiolabeled com-
pound is stable for more than 24 hours. Non carrier 
added experiments indicated a low reaction rate of 
complex formation (90% at f>6h) , however, good 
stability of the labeled molecule was demonstrated. 
Biodistribution studies in experimental animals with 
rhenium carrier-added preparations demonstrated rapid 
bone uptake and blood clearance, high renal excretion 
with negligible levels of activity in liver, thyroid and 
lungs. Good gamma camera images of rat and rabbits 
were acquired. The best quality of images were 
achieved with a single window centered at 155 keV, 
without beta shielding, with an MEHR collimator and 
2 cm distance between detector and source. These 
encouraging results will now be expanded to include 
dosimetric studies and clinical trials. 
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Summary 
Several efficient new methods for synthesizing rhenium com-
pounds containing a multiply bonded imido linkage (Re=N-R) 
between the metal and organic compounds for radiopharmaceu-
tical applications are reported. The imido linkage is stable and 
compatible with typical organic functional groups, and offers 
distinct structural and synthetic advantages over other types of 
linkages commonly used in radiopharmaceutical design. Syn-
theses of representative peptide and steroid compounds from hy-
drazine and phosphinimine imido precursors are described, and 
the preparation of a ,88Re-imido complex is discussed. A promis-
ing new I88Re-radiolabeling strategy for directly synthesizing 
rhenium imido radiopharmaceuticals, targeted for low-capacity 
receptor sites relevant for cancer therapy and based on solid 
supported imido precursors, is presented. 
The conjugation of radionuclides to biochemical re-
ceptor ligands provides a powerful method for the 
selective delivery of radiopharmaceuticals to target 
cells and organs for diagnostic imaging and thera-
peutic applications [1], Recently a great deal of inter-
est has focused on 188Re-bioconjugates prepared from 
peptides, antibodies, and steroids due to the potential 
of these compounds for selectively localizing in cancer 
cells, and the suitability of the radioisotope's energetic 
γ and /J-particles for imaging and radiolysis (respec-
tively) of small- to medium-sized tumors [2], The de-
velopment of convenient tungsten-188/rhenium-188 
generator systems, analogous to the widely used 
molybdenum-99/technetium-99m generators, provides 
access to this valuable radionuclide [3]. Two critical 
issues facing the development of 188Re radiopharma-
ceuticals for cancer therapy are i) the need for com-
pounds that will accumulate at tumor sites with high 
selectivity, and ii) the development of synthetic 
methods for producing these compounds in a clinical 
environment. The strategic targeting of low-capacity 
receptor sites on tumor cells provides a mechanism for 
selective binding, but raises a significant new synthetic 
challenge as well. Most of the currently available syn-
thetic methods use a large excess of derivatized recep-
* Presented at the Symposium on Radiochemistry and Radio-
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tor ligand relative to radionuclide in order to maximize 
the radiolabeling efficiency. A caveat to those ap-
proaches is that the non-labeled receptor ligands must 
be separated in order to avoid saturating the receptor 
sites with non-radioactive ligands, which would limit 
the effectiveness of the radiotherapy. While this sepa-
ration is possible using modern chromatographic tech-
niques, it requires additional equipment, and increases 
the preparation time and exposure during handling. 
These issues are particularly important when evaluat-
ing the feasibility of radiolabeling syntheses in a clini-
cal environment. The synthetic challenge is to develop 
new methodology for directly synthesizing 188Re-biocon-
jugates without requiring an additional separation step. 
Our interest has focused on using the multiply 
bonded organoimido group [4] (M=NR) as a strong, 
covalent linkage between a Rev metal center and bio-
logically relevant organic compounds. The use of an 
imido linkage potentially offers a number of advan-
tages over traditional approaches involving multi-hap-
to or chelating linkages. Namely, the imido i) requires 
only a single point of attachment between the metal 
and biomolecule, thereby ii) reducing the size of the 
linkage and iii) allowing the remaining coordination 
sites on the metal to be easily varied with ligands that 
would enable tuning of desirable properties (solubility, 
charge) in order to achieve optimal biodistribution. 
Complexes of the general formula [(PPh3)2Cl3Re= 
N - R ] containing stable, isotopic rhenium and in-
corporating simple (R = aryl or alkyl) organic com-
ponents are well known, and can be prepared by re-
acting the oxo complex [(PPh3)2Cl3Re=0] I with 
phosphinimine [C6H5-N=PPh3] [5] or hydrazine 
[CsHs-NHNHCOCHa] [6] derivatives. The synthetic 
availability of the carrier free 188Re oxo complex *I 
[7] makes these routes potentially viable for the syn-
thesis of radiopharmaceuticals, however the stability 
and compatibility of the imido group in the presence 
of organic functional groups was unknown when our 
investigation was initiated. In this presentation, we de-
scribe the syntheses of a variety of imido rhenium 
complexes containing functionalized, biologically 
relevant organic groups, and report a powerful new 
strategy for direct Re-labeling which produces product 
free from unreacted ligand. 
We recently found that the Rev oxo complex I re-
acts rapidly with functionalized N-acetyl-arylhydra-
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Scheme 1. Synthesis of functionalized Re imidos from arylhydrazine precursors. 
zine derivatives and triphenylphosphine in a refluxing 
1:1 mixture of toluene and 2-propanol to give the 
green, air stable aryl organoimido complexes II-IV 
(Scheme 1) [8]. 
The reactions proceed in high yields 85%) and 
no precautions against air or water in the reagents are 
required. The complexes have been fully characterized 
spectroscopically (NMR, IR, elemental analysis) and 
the X-ray structure of complex IVb has been deter-
mined. 31Ρ{Ή} NMR provides a very useful means of 
identifying the complexes where a characteristic single 
resonance at ca — 22ppm for the ira/is-equivalent 
phosphine ligands is observed. The FT-IR spectra of 
the complexes display absorptions in the usual ranges 
for the carbonyl groups of the esters, amides and acids 
in the complexes. These complexes have also been 
characterized by HPLC utilizing a reversed-phase col-
umn (C8 on silica), and eluted without decomposition 
in aqueous acetonitrile. To our knowledge, complexes 
Ila-IVa represent the first examples in which an or-
ganoimido ligand and free carboxylic acid groups are 
present within the same molecule [9], The efficient 
R e - Ν π-bonding in these organoimido complexes re-
sults in the weak basicity/nucleophilicity of the nitro-
gen atom and imparts stability to the complexes 
against detectable hydrolysis in the protic media used 
for HPLC. The complexes were also stable in acetoni-
trile mixtures containing up to 10% acetic acid. Furth-
er investigations of the stabilities of these complexes 
under physiological pH, and in the presence of biologi-
cally relevant ligands are in progress. 
To test the viability of extending this chemistry to 
the tracer level, a synthesis of IVb labeled with 1S8Re 
was carried out starting from a CH2C12 solution of 
[188Re(0)Cl3(PPh3)2] (I*) prepared by the literature 
method [3], Reaction of I* with an excess of the 
acetylhydrazine and PPh3 proceeds smoothly at room 
temperature to produce [188Re(NC6H4(CH2)3C02Et)-
Cl3(PPh3)2] (IVb) in quantitative radiochemical yield 
as determined by HPLC with radiometric detection. 
The reactions between I and the 4-i-butylcyclo-
hexyl acetylhydrazine derivative CH3CONH—NH— 
C6H10C(CH3)3 or the isoelectronic methoxylamine de-
rivative CH30—NH—C6H10C(CH3)3 proceed rapidly at 
ambient temperature in CH2C12 to give the product 
alkyl organoimido complex [(PPh3)2Cl3Re=N— 
C6H10C(CH3)3] (V) in 83% and 87% yields respective-
ly. Methoxylamines can be easily synthesized by the 
reduction of methoximes with NaBH3CN, and rep-
resent new, convenient precursors for alkyl imido 
complexes. Functionalized alkylimido complexes 
[(PPh3)2Cl3Re=N—X]; (X = -(CH2)5OH (VI); 
—(CH2)4CH(0H)C02Et (VII)) were also prepared in 
75% and 80% yields respectively by this route. The 
chemistry was then extended to prepare a dihydrocho-
lesterol derivative VIII from the corresponding me-
thoxylamine. The reaction between I and the equa-
torially substituted methoxylamine produced VIII in 
excellent yields (85—92%), while the sterically hin-
dered axially substituted diastereomer was unreactive 
under these conditions. 
(Ph3P)2CI3Re =N -
VIII 
The reaction between I and functionalized phos-
phinimines [Ph3P=N—C6H4—X] provides another ef-
fective route for preparing the aryl organoimido com-
plexes. Ester and amide derivatives containing the 4-
azidobenzoyl group can be easily prepared from 4-azi-
dobenzoic acid, and these react readily with PPh3 to 
form the corresponding phosphinimines. The high 
basicity of the Zwitter-ionic phosphinimine is com-
patible with ester and amide derivatives but not 
unprotected carboxylic acid and alcohol groups [9]. 
The imido forming reactions with phosphinimines pro-
ceed rapidly in refluxing THF, and were used to syn-
thesize aryl organoimido complexes containing simple 
amino acid derivatives such as [(PPh3)2Cl3Re=N— 
QHtCO—Ala—OEt] (IX) in 92% yield, and also 
an imido complex attached by amide linkages to the 
two ornithine residues of the cyclic decapeptide 
gramicidin - S [((PPh3)2Cl3Re = N — C6H4C(0) - Orn -
Leu—Phe—Pro-Val—)2] (X) in 75% yield. 
The methodology presented thus far demonstrates 
the synthetic feasibility of imido-based rhenium radio-
pharmaceuticals. Consideration of the chemical simi-
larity of the imido precursors, in which a nitrogen-
heteroatom bond is cleaved during formation of the 
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N3—C6H4-C02-Cholest. 
A 
+ -N2(g) 
^ - ( c 6 H 4 - P P h 2 ) 
[c6H4 -P=N-C6H4 -C02 -Cholest.) 
+ 0.2 equiv. Re(0)CI3(PPh3)2 (I) 
CH2CI2 
ic6H4 -P=N-C6H4 -C02 -Cholest.) 
( C 6 H 4 - P = O ) 0 
n-0.2 equiv. 
2 equiv. (CH3)2CH(CH2)3 
(Ph3P)2CI3Re=N-C6H4-C02^ ή 
XI 
Scheme 2. Synthesis of a rhenium imido-cholesterol complex from a solid support. 
imido bond, led us to investigate the possibility of 
using a solid-supported imido precursor for synthesiz-
ing the product Rev imido compounds free from unre-
acted ligand. The key feature of this conceptual ap-
proach is that the Re-labeling step simultaneously 
cleaves the product imido complex from the polymeric 
support, leaving unreacted imido precursors attached 
to the support at the end of the reaction. 
This strategy has been successfully applied to the 
synthesis of a cholesterol derivative as shown in 
Scheme 2. The 4-azidobenzoyl ester imido precursor 
(A) is prepared from dihydrocholesterol and 4-azido-
benzoic acid, and then reacted with 2% crosslinked 
polystyrene-triphenylphosphine to form the solid sup-
ported phosphinimine (B). The reaction of Β with I 
takes place in CH2C12 at ambient temperature, produc-
ing the green imido product XI, isolated in 95% yield 
after simple filtration to remove the unused resin C. 
In conclusion, we have demonstrated that com-
plexes containing metal imido bioconjugates are com-
patible with common organic functional groups, are 
easily prepared in high yields from actylated arylhy-
drazine, methoxylamine and phosphinimine precursors, 
are stable against hydrolysis, can be prepared in high 
yields at the tracer level, and by solid phase synthesis. 
The further development of solid supported organoim-
ido precursors for synthesizing 188Re radiopharmaceu-
ticals in a clinical environment are currently in pro-
gress. The successful implementation of this method-
ology can potentially lead to simple "instant-kits" for 
preparing radiopharmaceuticals targeted for the low-
capacity receptor sites on certain cancer cells, which 
will enable their treatment by radiotherapy. 
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Yttrium /Antibodies / Radioimmunotherapy / 
Chelates / Stereochemistry 
Summary 
The unusual stereochemical influence on in vivo stability of 
the two C-Functionalized cyclohexyl diethylenetriamine-
N,N,N',N",N"-pentaacetic acid (CyDTPA) chelating agents, 
(CHX—A, CHX—B), recently reported warranted further inves-
tigation to determine why such differences in configuration pro-
duce such striking effects on the stability of the Yttrium com-
plex. To this end, all four individual component stereoisomers 
of CHX—A and CHX—Β were synthesized for a detailed inves-
tigation into their chelation chemistry. Results of transchelation 
measurements, serum stability studies, and in vivo femur deposi-
tion measurements with 88Y indicate that the 88Y—CHX—A che-
lates are significantly more stable, in vitro and in vivo, than the 
88Y—CHX-B complexes. Additionally, significant difference in 
vivo between the 88Y complexes formed from the component 
enantiomeric ligands were observed. 
Introduction 
Use of radiolabeled monoclonal antibodies (mAbs) for 
the diagnosis and therapy of malignancies continues 
to receive attention [1]. A variety of metallic radio-
nuclides have been employed to expand the choices of 
emission characteristics and half-lives for diagnostic 
(γ and β+ emitters) and therapeutic (/?" and a emitters) 
applications [2, 3]. 
We had previously reported the synthesis of the 
C-functionalized cyclohexyl diethylenetriamine-
N,N,N',N",N"-pentaacetic acid (CyDTPA) chelating 
agents, CHX-A and CHX-B DTPA (Fig. 1), their 
evaluation for in vivo stability with 212Bi, and that both 
ligands were excellent at sequestering Bismuth radio-
nuclides [4—6]. However, we later reported an unex-
pected result upon evaluation of these two ligands with 
88Y. The 88Y—CHX—A complex, linked to mAb B3, 
was found to be equivalent to the 88Y-1B4M-DTPA 
while the88 Y-CHX—Β complex, under the same con-
ditions, was remarkably unstable both in vitro and in 
vivo [7]. 
Clearly, since CHX-A and CHX-B are dia-
stereomers, different chemical properties were to be 
expected and were even relied upon for the isolation 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
CHX-A CHX-B 
Fig. 1. Structure of the C-functionalized CyDTPAs, CHX-A 
DTPA and CHX-B DTPA, and their constituent enantiomers 
CHX - A', - A", - B', - B " . 
of the two compounds. However, large differences in 
in vivo stability for complexing 88Y while being found 
equivalent for complexing 212Bi in an active biological 
milieu prompted further investigation of these ligands. 
Having observed that stereochemistry could be a 
significant variable effecting in vivo complex stability, 
some concern was expressed that even using pairs of 
enantiomers, such as CHX—A itself, could be yet 
masking some additional, subtle level of stability, or 
instability, that should be resolved. To eliminate all 
doubt as to the results obtained from study of the 
stability of the Yttrium complexes, stereospecific syn-
thesis and evaluation of each of the four stereoisomers 
that comprise CHX-A and CHX-B DTPA's was pro-
posed. 
Herein, we report the correlated results for the first 
evaluation of the 88Y complexes of the four stereo-
isomers of the C-functionalized CHX—A and CHX— 
Β DTPA's, their individual serum stability, transchela-
tion, and in vivo stability as determined by 88Y deposi-
tion at the femur of mice. 
Experimental 
Reagents 
All chemicals and solvents were purchased from either 
Fluka, Sigma, or Aldrich. The (7)-/?-nitrophenyl-
alanine was obtained from Research Organics while 
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Fig. 2. Stereospecific synthesis of CHX-A'-DTPA. 
the (d) was purchased from Bachem (CA). The trans-
(R,R)- and (S,S)-l,2-diaminocyclohexanes were pur-
chased from Fluka. Production of mAb B3 has been 
described in detail elsewhere [8], 88Y (YC13 in 0.1 Μ 
HCl) was obtained for Los Alamos National Labora-
tory. 
Ligand synthes is and con juga t ion 
Appropriate permutation of reagents was applied to the 
syntheses of the component enantiomers of the CHX-A 
and CHX-B DTPA's ( C H X - A ' , - A " , - B ' , - B " ) as 
depicted in the general synthesis scheme (Fig. 2). All 
syntheses were performed as previously reported in the 
literature for the LRR or CHX-A' -DTPA and were 
fully characterized [5]. 
In brief as a general example, synthesis of 
CHX-A' -DTPA (Fig. 2) was performed by diimide 
coupling of chiral carbamate protected p-nitro-
phenylalanine with the mono-carbamate protected chi-
ral diamine. This amide was then deprotected with 
33% HBr/Acetic acid (Fluka) and the resulting di-
amine reduced with diborane. The crude triamine re-
duction product was alkylated directly with tert-butyl 
bromoacetate. After ester cleavage with trifluoroacetic 
acid, the product was isolated by preparative HPLC 
and purified by anion-exchange chromatography. The 
aryl nitro group was hydrogenated and the aniline con-
verted to an isothiocyanate by treatment with thiophos-
gene. A detailed report on the syntheses and purifica-
tion has been accepted for publication [9], 
The mAb B3 was concentrated to ca. 5 mg/mL and 
dialyzed into 0.1 Μ HEPES, 0.15 Μ NaCl, pH 8.5. 
The mAb solutions were then conjugated to each of 
the four enantiomers, respectively, and purified as pre-
viously described [10]. The average number of che-
lates per antibody for each enantiomer was determined 
to range between 1.5—2.0 for the four preparations 
[11]-
Radio labe l ing of B3 — C H X - D T P A 
con juga tes 
Carrier free 88Y (5 mCi) was first purified by ion-ex-
change chromatography (Re.Spec resin, EiChrom, 
Inc.). In brief, stock solution was mixed with an equal 
volume of conc. HN03 and heated to dryness. The ac-
tivity was dissolved in 2 Μ HN03 and passed through 
the resin. The fractions containing the 88Y were col-
lected, heated to dryness, taken up in 0.1 Μ HN03 and 
used for radiolabeling. The pH of the 88Y solution was 
adjusted to ca. 6.0 with 3 Μ NH4OAc and the B3 con-
jugate was added. After incubating for 30 min, the ra-
diolabeled protein preparation was purified by HPLC 
using a TSK-3000 column eluting with PBS (pH 7.2, 
0.1 M) at 1.0 mL/min. Yields were 85-90% for all 
four CHX isomers conjugated to B3. Specific activity 
for the four preparations ranged from 1.5—1.6 mCi/ 
mg. Immunoreactivity of each preparation was deter-
mined by described methods [12], 
Serum stabil i ty 
The p -N0 2 -Bz form of the CHX-A',A",B',B" DTPA 
isomers were labeled with 88Y and their serum stability 
was evaluated over 17 days. Briefly, 25 μ ί of each 
stock ligand solution (4 Χ10 4 M) were mixed with 
55 -60 μ α of 88Y in 0.1 Μ HN03, and the pH was 
adjusted to 5.5-6.5 with 3 Μ NH4OAc. The reaction 
mixture was incubated at 37 °C for 30 min. The com-
plexes were purified by Chelex-100 resin (Bio-Rad, 
3 X15 mm), eluted from the resin with H20 (0.5 mL), 
and diluted to 1.0 mL. In every case, labeling ef-
ficiencies were ^90%. 
Aliquots (100 μΐ) of each 88Y-labeled ligand stock 
solution (1.0 Χ10"5 M) were then mixed with 9.9 mL 
of normal human serum (final concentration 1.0 X 
10"7 M), passed through a sterile 0.22 μπι filter (Milli-
pore Co., Bedford, MA), aliquoted (0.8 ml) into 12 
sterile culture tubes and incubated at 37 °C in a C02-
enriched atmosphere (5% C02). 
The percentage of dissociated 88Y was assessed by 
paper chromatography (Whatman No. 1) using PBS as 
the mobile phase. All 88Y-labeled ligands showed Rf 
values ca. 1.0, whereas in the control experiments, less 
than 1% of free activity migrated above the top half 
of the paper (Rf > 0.5). 
Transchela t ion 
Reaction mixtures were prepared by mixing appropri-
ate amounts of each 88Y labeled B3 conjugate prepared 
above such that the concentration of components was 
1 X 10~7 Μ for the chelate, 0.01 Μ in DTPA, and 
1 mg/mL in human IgG (carrier protein to prevent 
non-specific adsorption of B3), pH 5.0 (0.1 Μ 
NH4OAC) or 7.2 (0.1 Μ HEPES). The mixtures were 
sterilized by filtering them (0.22 μπι filters) into sterile 
culture tubes which were then tightly capped, and in-
cubated in a 37 °C water bath. 
The percentage of 88Y transchelated to DTPA from 
each 88Y labeled B3—CHX—DTPA isomer was meas-
ured by using size exclusion HPLC (7.8 mm X 30 cm, 
TosoHaas, Japan) with elution of PBS at 1.0 mL/min. 
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Fig. 3. Serum stability of 8 8Y-CHX-DTTA complexes. 
Biodis t r ibu t ion (Femur depos i t ion) 
Non-tumor bearing athymic mice were given i.v. 1 — 
2 μ α of the 8 8Y-CHX-DTPA preparations (10 mice 
per time point). The mice were sacrificed (24, 48, 96, 
and 168 h) and a modification of the reported method 
was applied for determining uptake of 88Y in cortical 
bones [6]. In brief, a femur was removed from each, 
broken longitudinally, incubated with PBS for 30 min 
and then washed again with PBS. The bone was then 
washed with PBS/10% SDS for 1 hr at 56 °C, centri-
fuged, and then washed again with PBS. The activity 
in the bone was counted after being blotted dry and 
weighed to determine percent injected dose per cortex 
of the bone. 
Results and discussion 
Synthesis of the four stereoisomers (Fig. 2) was large-
ly unremarkable as the chemistry employed has been 
described in detail elsewhere [5]. A point of interest 
concerning a consistent difficulty encountered in the 
BH3 reductions was a tendency for reduction of the 
aryl nitro group to the aniline. This complication could 
be minimized by careful titration with BH3, but not 
eliminated, and as such, occasionally resulted in in-
complete reduction of the amide. Thus, the triamines 
were not isolated, but rather directly alkylated, with 
purification occurring at the pentaacetic acid stage for 
each stereoisomer. 
Determination of serum stability of the 88Y labeled 
stereoisomers CHX—Α',—Α",—Β',Β" revealed no sig-
nificant revealed no significant differences between 
the complexes formed from the enantiomeric pairs and 
the corresponding racemate (Fig. 3). The results essen-
tially reproduced and confirmed the earlier report [7] 
that the88 Y-CHX—Β complex was significantly more 
unstable in serum as compared to the 88Y—CHX—A 
complex for both enantiomers and racemates. 
Somewhat more interesting were the results from 
the transchelation experiments wherein each 88Y com-
plex was challenged with a large excess of DTPA 
Time (Hours) 
Fig. 4. Transchelation of 88Y from 8 8Y-CHX-DTPA mono-
clonal antibody B3 conjugates. 
(Fig. 4). At pH 7.2 this reaction was too slow (<0.5% 
per 24 h) to be relevant when applied to the topic of 
relatively short-lived radioisotopes. To obtain results 
during a meaningful time frame, the experiment was 
conducted at pH 5.0. Again, the trend of the 88 Y— 
CHX—Β complex being less stable, (ca. 85% loss of 
88Y after 12 h) than the 8 8 Y - C H X - A complex (ca. 
85% loss of 88Y after 24 h) was observed and as before 
for serum stability, the results for the individual 88Y 
labeled enantiomers were essentially identical to the 
results for the racemate. While small differences in 
rate could be suggested between enantiomers, these 
were relegated to being due to experimental error. 
However, a curious result that continues to be studied 
was the biphasic rate of transchelation observed during 
the study for all of the compounds. Additionally, after 
rapidly losing 90% of the complexed 88Y by 24 h, the 
88Y-CHX—Β complexes appear to be rather stable for 
the remaining fraction of the complex as compared to 
the 8 8 Y-CHX-A. At this time, no explanation is 
readily available and this observation continues to be 
studied. 
A striking result was obtained upon in vivo evalu-
ation of the 88Y labeled B3 conjugates (Fig. 5). The 
femur was chosen as the most critical part of the body 
to evaluate for 88Y deposition due to the lanthanides 
and Yttrium being bone-seekers when released in vivo 
[12]. While the general trend of the 8 8 Y - C H X - B 
complexes being less stable than the 88Y—CHX—A 
complexes was observed, resolution of significant dif-
ferences between the 88Y labeled conjugates was 
clearly obtained. A large difference was readily ob-
served between the ^ Y - C H X - B ' and 8 8 Y-CHX-B" 
complexes after 24 h which continued to increase 
throughout the time course of the experiment with the 
88Y—CHX—B' conjugate being least stable of all. Of 
greatest importance was the small, but significant dif-
ference (p < 0.05, Student T-Test) recorded for the 
88Y—CHX—A" versus the 8 8 Y - C H X - A ' conjugate, 
wherein the former was found to be slightly more 
stable than the latter, consistantly with the lowest 
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Fig. 5. 88Y bone uptake from 8 8Y-CHX-DTPA monoclonal 
antibody B3 conjugates in mice. 
deposition of 88Y to bone. This experiment was re-
peated for two time points for the two 8 8Y—CHX—A 
enantiomers with a near identical result being ob-
tained. 
The significance of such a result is of paramount 
importance and implies that if one chooses the proper 
stereochemistry, the geometry of the coordination 
sphere can be optimized to obtain better chelating 
agents. Use of chelating agents for radioimmuno-
therapy and imaging must meet the minimum require-
ments of kinetic and thermodynamic stability in vivo. 
Failure to meet this pre-requisite leads to in vivo dis-
sociation of the isotope and its subsequent deposition 
into organs which contributes to toxicity. These results 
demonstrate that ligand stereochemistry is a factor that 
should be considered in the design of new bifunctional 
chelating agents for Nuclear Medicine applications. 
Conclusions 
Ligand stereochemistry, largely discounted as a factor 
in the stability of polyaminocarboxylate ligands used 
for radioimmunoimaging and therapy, was found to be 
quite relevant to the stability of the four configurations 
of the C-functionalized C H X - D T P A ' s . To the best of 
our knowledge, differences in complex stability be-
tween enantiomeric ligands has not been reported in 
the literature and implies that the metal ion itself exerts 
a stereochemical influene to produce complexes that 
are inequivalent in a biological milieu. The limitations 
of serum stability and transchelation experiments were 
demonstrated by the inability of these methods to re-
cord the results comparable to those obtained via bio-
distribution. 
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Summary 
We have been investigating the use of the alpha-emitting radio-
nuclide 2,2Bi against microscopic carcinoma. Our in vitro studies 
show that 212Bi is 2 to 4 times more effective in eradicating 
microscopic cells grown in monolayer or multicellular spheroid. 
Autoradiographs show that 212Bi diffuses within the spheroids 
by 2 hours after exposure. There was no difference in cell kill if 
cells were grown in monolayer or 100 μπι and 800 μιη sphe-
roids. From our study, 212Bi appears to be a suitable candidate 
to investigate for clinical use against microscopic carcinoma. 
Introduction 
Alpha (a)-emitting radionuclides are being investi-
gated for therapy against microscopic cancer [1], This 
class of radionuclides have properties that make them 
attractive in that it is densely ionizing, delivers high-
LET radiation, and its effect is not limited by the pres-
ence of oxygen. The radionuclide we are interested is 
Bismuth-212 (212Bi). It is generated from the decay of 
Thorium-228 to Lead-208. In its decay 95% of the 
energy is derived from emission of α-decay [2]. 
Prior to testing 212Bi in the clinical setting, its ef-
fect against cells grown in an in vitro system needs 
investigation. Previous in vitro studies have shown a-
emitting radionuclides to increase killing compared to 
X-rays when cells are grown in monolayer [3]. How-
ever, in clinical situations microscopic carcinoma can 
be defined either as no evidence of visible disease or 
as the presence of multicellular clusters of cells. To 
simulate the latter situation, a model can be used 
whereby cells are grown as spheroids [4]. Since our 
intention is to develop 212Bi for therapy against micro-
scopic carcinoma, in this study we investigated its 
effect against killing microscopic cells grown either in 
monolayer or in spheroids. 
Materials and methods 
Cell l ines 
Two cell lines were used: a Chinese hamster fibroblast 
cell line (V-79) and a human ovarian epithelial carci-
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
noma cell line, (NIH:OVCAR-3). Cells were main-
tained under exponential growth conditions in a-MEM 
medium supplemented with 10% fetal calf serum, 100 
units/ml penicillin, 100 μg/ml streptomycin, and 2 mM 
L-glutamine. 
Spheroid format ion 
To initiate spheroids, cells were cultured on plates con-
taining 5% Bacto-agar diluted to 2% with serum-free 
medium at a concentration of 500,000 cells/flask. 
After multicellular spheroids of a minimum size were 
formed they were maintained until they reached a size 
between 10—1000 μπι. This took about 2 weeks for 
V-79 cells and 3 weeks for NIH:OVCAR-3 cells. Just 
before irradiation, spheroids were sized and separated 
using a spheroid separation column. This column uses 
a nylon monofilament screen fabric to separate the 
spheroids based on size. The spheroids were sized and 
counted. Spheroids of 100 μπι and 800 μπι were used. 
X-ray teatment 
X-ray treatment of cells were done with a GE 250kvp 
Maxitron Unit operated at 26 mA° (HVL of 1.6 mm 
Cu) at a dose-rate of 1.11 Gy/min. Cells were exposed 
at room temperature and then immediately plated for 
survival. 
32P treatment 
32P chromic phosphate was purchased form Mallinck-
rodt Chemicals, St. Louis, Mo. Cells were exposed to 
32P chromic phosphate at room temperature in plastic 
tubes. To deliver a given dose the dose^Ci was calcu-
lated and corrected for decay. The dose was calculated 
using the expression 
Dose (cGy)^Ci-hr = 1.33 Χ108 disintegrations/hr^Ci 
X 1.71 MeV X 1.61 X106 erg/MeV/vol(ml) 
X100 erg/ml-cGy . 
The dose was based on the assumption that the 
radionuclide distributed uniformly during exposure. 
Cells were maintained in suspension with micromag-
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netic stirrers. After exposure cells were washed three 
times in phosphate-buffered saline (PBS) and then 
immediately plated for survival. After exposure, the 
medium was counted and the dose recalculated to cor-
rect for pipetting error. 
212Bi treatment 
212Bi was obtained from a generator system developed 
by Rotmensch et al. [5]. The 212Pb parent was pro-
duced from a 224Ra system that has been described by 
Atcher et al. [6]. After elution of 212Bi, the acid was 
neutralized with 150 μΐ of 4 Ν sodium acetate to pH 
5.0—7.4. The 212Bi solution was then filtered through 
a 0.22 μηι Millex GV filter prior to treating the cells. 
The filter was purged with 1 ml of distilled deionized 
water. The radioactivity was assayed using a 3X3" 
Na(Tl) well detector. The detector output was fed into 
a 4096 channel multianalyzer (Davidson 4106, North 
Haven, Ct.). The 583 keV y-ray for 208T1 was used to 
determine the activity. 
Cells were exposed to 212Bi in suspension to de-
liver the desired doses over a 4 hr exposure time. The 
dose was determined by a method described by 
Schwartz et al. [6], Dose^Ci was calculated using the 
expression: 
Dose (cGy)^Ci-hr = 1.33 X108 dph/μα X 7.8 MeV 
X 1.6 X 10 6 erg/MeV/vol (ml) X 100 erg/ml-Gy . 
Calculation was based on the assumption that there 
was uniform distribution of the radionuclide during the 
exposure time. Exposure was terminated by washing 
cells three times in PBS before plating for survival 
determinations. After exposure the medium was 
counted and the dose again calculated to correct for 
decay and pipetting errors. 
Survival measurements 
Immediately after irradiation, 100- 20,000 cells were 
plated into 10 ml of complete medium in 10X20 mm 
Petri plates (4 plates/dose point). Plates were stained 
with crystal violet and colonies greater than 50 cells 
scored. All experiments were run in triplicate. From 
the survival curves, the radiationsensitivity (Do) was 
determined as described by Hall [7]. 
Data analysis 
Regression analysis was done using Minitab data 
analysis software (Minitab, Inc.) [8]. Statistical signifi-
cance was determined using Fisher exact test. Results 
were determined as mean ± standard error of the mean 
for 3 to 6 independent values. 
Autoradiography 
At hourly intervals after exposure to 212Bi, spheroids 
were frozen, dehydrated, and fixed in acetone. Slides 
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Fig. 1. Survival of cells grown in monolayer treated with X-ray, 
32P, and 212Bi, showing increased cell kill with 212Bi. 
Fig. 2. Electron micrograph of spheroid used for in vitro studies. 
containing individual thin layer sections were dipped 
into NTB-3 emulsion (Kodak, Rochester, N.Y.) and 
stained with hematoxylin and eosin [9]. 
Results 
212Bi was more effective than X-ray or 32P in killing 
either V-79 or NIH:OVCAR-3 cells grown in mono-
layer. The radiosensitivity (Do) ranged from 0.7—0.9 
Gy after 212Bi, 1.7-1.5 Gy after 32P, and 1.8-2.2 Gy 
after X-ray therapies for the two cell lines (Fig. 1). 
There was no difference in the radiosensitivity of the 
two cell lines. The relative biological effectiveness 
was 2.2 to 2.4 times greater for 212Bi compared to X-
ray therapy. 
Electron micrographs of the spheroids before treat-
ment showed them to be three dimensional (Fig. 2). 
Treating spheroids with 212Bi caused a similar effect as 
seen with those in monolayer. 212Bi was more effective 
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Fig. 3. Survival of cells grown in to spheroids showing increased 
cell kill of 212Bi compared to X-ray and 32P. 
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Fig. 4. Equal survival of 100 μπι and 800 μπι spheroids after 
4 hour exposure to 2,2Bi. 
in killing spheroids than 32P and X-rays. Do ranged 
from 0.6-0.7 Gy after 2t2Bi therapy; 2.5-2.7 Gy after 
32P therapy; and 2.5-2.8 after X-ray therapy (Fig. 3). 
The relative biological effectiveness was 4.2 to 4.8 
times greater with 212Bi than X-rays. The radio-
sensitivity of 100 μπι spheroids were similar in both 
cell lines. There was no difference in radiosensitivity 
for 100 μηι and 800 μπι spheroids grown from 
NIH:OVCAR-3 cells. Do was 0.7 Gy for both size 
spheroids (Fig. 4). 
Autoradiographs showed that 212Bi distributed 
throughout the spheroid within a short time. At 2 hours 
activity is seen homogeneously throughout a 800 μπι 
NIH:OVCAR-3 spheroids (Fig. 5). 
Fig. 5. Autoradiograph of center of 100 μπι spheroid showing 
212Bi diffused onto cell. 
Discussion 
212Bi appears to be a suitable candidate to investigate 
for therapy to eradicate microscopic cancer. Unlike the 
low-LET of conventional radiation used, it is high-
LET and densely ionizing. It has a short half-life on 
only 60.6 minutes having the ability to deliver its 
energy to a region rapidly while minimizing exposure 
of normal structures. 
Because of the short half-life a problem has been 
the production of quantities of 212Bi that are clinically 
useful. Atcher et al. developed a system to generate 
212Bi through the decay of Radium-224 [10]. However, 
with the generation of large quantities of 212Bi there is 
degradation of the support system allowing break-
through of unwanted long-lived parent radionuclides. 
We have recently developed a new system based on 
the decay of 212Bi and growth of 212Pb [5], Our belief 
is that this system will be more useful for clinical trials 
in that up to 30 mCi of 212Bi has been produced with 
no significant radiocontamination. Since it is our 
intention to use the system we developed for early 
clinical use, this source of 212Bi was used for in vitro 
studies. 
Prior to proceeding to in vivo trials, we decided to 
test the effect of 212Bi against microscopic disease in 
an in vitro model and compare its effect to conven-
tional radiotherapy (X-ray and the /^-emitter 32P). For 
these studies two cell lines were chosen. Our first 
studies were done using the cell line V-79. This is a 
Chinese hamster lung fibroblast cell line. It was 
chosen because it has been used in many previous ra-
diobiological studies with X-ray therapy [11]. How-
ever, since our intention is initially to treat women 
with adenocarcinoma of the ovary, we believed that it 
was more relevant to study a human ovarian adenocar-
cinoma. For this reason we chose the NIH: OVCAR-3 
cell line. This is a well characterized human cell line 
that was established from ascites of a patient with 
adenocarcinoma of the ovary. 
In our early studies the effect of 212Bi against cells 
grown in monolayer was investigated [3], This ex-
trapolates to a clinical situation where there is no evi-
130 J. Rotmensch, J. L. Whitlock, J. L. Schwartz and J. J. Hines 
dence of carcinoma but a patient is at high risk for 
recurrence. In this circumstance, 212Bi was 2 to 4 times 
more effective in killing cells than X-ray or 32P regard-
less of the cell line used. 
In most clinical situations, cells are not present as 
individual cells but as clusters of microscopic cells. 
Cells grown in vitro as spheroids may better represent 
this situation. Spheroids are multicellular, have cell to 
cell contacts and areas of necrosis [4], The necessity 
for studying cells in spheroids is that the results of 
monolayer studies often cannot be extrapolated to mul-
ticellular spheroids. With V-79 cells different effects 
have been reported with X-ray for cells grown in 
monolayers and those in spheroids. Van Leeuwen-Stok 
et al. found treating cells with the Auger emitter 67Ga 
single cells were more sensitive than spheroids [12]. In 
our study, regardless of the cell line used for spheroid 
formation, 212Bi was 2 to 4 times more effective in 
eradication of the spheroids regardless if 100 μηι and 
800 μπι spheroids were treated. 
We postulate that the increased cell kill may be 
caused by the rapid absorption of 212Bi through the 
spheroid. Autoradiographs of cross sections show that 
the activity is not only deposited on the surface but is 
absorbed within 2 hours. This is in contrast to assump-
tions made in computerized modeling of dosimetry 
that activity is a static process and is only on the sur-
face of a tumor mass [13]. These modeling systems 
do not take into account the diffusion of activity over 
time. 
Our earlier studies focused on the use of 212Pb as 
a colloid of ferrous hydroxide [1]. At this time, we do 
not believe that this preparation is most optimal for 
intraperitoneal therapy. A requirement of using this 
route of administration in patients is that there is uni-
form distribution throughout the peritoneal cavity. Our 
preliminary in vivo work has showed that 212Pb ferrous 
hydroxide does not evenly distribute but rapidly settles 
forming radioactive hot spots. In contrast based on our 
animal studies 212Bi distributes evenly throughout its 
decay. Our initial goal is to develop the use of 212Bi in 
as a non-specific therapy. However, the potential exists 
of also developing this therapy as a directed therapy 
by chelating it to an antibody [14]. 
From our studies, it appears that 2,2Bi is a suitable 
candidate to further study for development of therapy 
against microscopic cancer. Our future studies are 
aimed to determine the in vivo effects of 212Bi. We 
are planning to study the distribution and associated 
toxicity in animal models. In addition, we are improv-
ing the method of producing this radionuclide. 
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Summary 
Conventional Szilard Chalmers experiments using unstable 
organometallic compounds usually fail to scale up with in-
creased irradiation time and neutron flux. An alternative, in-
organic-based, Szilard-Chalmers system involving rhenium 
metal films or insoluble, mixed-metal oxides, in a level of sev-
eral millicuries, for enhancement of the specific activity of (η, γ) 
,86Re and ,88Re is being evaluated at MURR. This system has 
consistently yielded enrichment factors of greater than 3 with a 
neutron flux of 8 X 10" n/cm2/s for several irradiation hours. 
Introduction 
For a number of years, 186Re has been of interest to 
the nuclear medicine community for use in therapeutic 
applications [1—5], It is a beta-emitting radionuclide 
with a maximum energy of 1.07 MeV and a decay half 
life of 89.25 hours. It also emits a 137 keV gamma ray 
in 9.2% abundance suitable for evaluation of in vivo 
distribution of rhenium agents. 
The principal drawback to 186Re for radio-
immunotherapy or receptor agent-guided radiotherapy 
is the production method utilizing the (η, γ) reaction in 
a nuclear reactor. Although the thermal and epithermal 
neutron cross sections for 185Re are high (106 b and 
1632 b, respectively), the specific activity of 186Re 
which can be produced in a reactor such as University 
of Missouri Research Reactor (thermal neutron flux 
4.5 Χ1014 n/cm2/s) is only about 3 Curies/mg Re at 
end of irradiation, which is considered marginal for 
radioimmunotherapy at the present time. Since only 
a handful of reactors with higher neutron fluxes are 
operating in the world, methods of enhancing the spe-
cific activity of 186Re by other means are desirable. 
It was recently reported that no-carrier-added 186Re 
was produced via a 186W(p,n)186Re reaction [6]. A 
99.79% enriched [186W]W03 target was irradiated with 
13.6 MeV protons at a beam current of ~ 3 μΑ. The 
apparent disadvantages of this accelerator production 
of no-carrier-added 186Re are the high production cost 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
and relatively low yield, which may limit this produc-
tion method to only the research stage. 
Conventional Szilard-Chalmers techniques, which 
utilize an organic Re complex as the starting material, 
take advantage of the ~6 MeV of excitation gamma 
energy emitted by the rhenium nucleus after thermal 
neutron capture to rupture organometallic bonds via 
the recoil energy [7—8]. This approach has been pro-
posed and evaluated by many investigators. Cohn et 
al. [9] reported irradiating a Re compound, Cp*Re03 
(pentamethylcyclopentadienyl rheniumtrioxide), in 
their reactor and observed that the activated com-
pounds (molecules containing hot Re atoms) decom-
posed to water soluble perrhenate while the rest of the 
molecules would remain in the organic phase. The 
specific activity of 186Re was enhanced by a factor 
between 400— 800 with neutron irradiation at 1.5 
Χ1013 n/cm2/s for 10 minutes. However, a Re target 
of this type is not allowed to be irradiated at our 
facility due to the potential safety problem. Szilard-
Chalmers reactions normally do not result in signifi-
cant specific activity enhancement in high neutron 
fluxes due to the increased radioactive (gamma and 
fast-neutron) decomposition of non-activated metal-
organic bonds. In other words, experiments using 
organic compounds frequently produce large enhance-
ment of specific activity for short irradiations in low 
neutron fluxes, but progressively fail to deliver en-
hanced specific activity product as irradiation time and 
neutron flux are increased. 
Alternative, inorganic-based, Szilard-Chalmers 
systems involving rhenium metal films or insoluble, 
mixed-metal oxides, have been investigated in our 
laboratories up to a level of several millicuries, for 
enhancement of the specific activity of (η, γ) 186Re and 
188Re. A number of rhenium targets were prepared and 
evaluated in the laboratory. The yield and enrichment 
factor were measured for the Szilard-Chalmers effect 
on neutron irradiated targets to investigate the feasi-
bility of this method of production of high specific 
activity 186Re. The basis of this process lies in the as-
sumption that lower oxidation states of rhenium will 
tend to react with oxygen to form water-soluble 
Re(VII) when provided with sufficient activation en-
ergy from the recoil process (which yields transient 
temperatures of many thousands of degrees Kelvin). 
Only natural rhenium targets have been used to date, 
as an enriched 185Re target has not yet been made in 
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the proper chemical form. Use of natural rhenium tar-
get also permits comparison between enhancement 
factors for 186Re vs. 188Re. Although these factors for 
188Re and 186Re have been relatively low (4-20), they 
have been reproducible. Of greater significance is the 
observation that scaling up from 5 second irradiations 
at 4 Χ 1013 thermal neutrons cm2/s to 30 minute ir-
radiations at the same flux did not significantly reduce 
the enhancement factor, indicating that the low en-
richment factors were probably due to the poor target 
preparation instead of radioactive decomposition. In 
any event, enhancement of the specific activity qf 
186Re by even a factor of 3—5, if it could be Ac-
complished at high neutron flux, would be sufficient 
to render 186Re a very attractive agent for rädio-
immunotherapy. The use of inorganic compounds, 
which in general are more resistant to radiation fields 
than organic or organometallic compounds, reinforces 
the reasonableness of this suggestion, while the utter 
simplicity of the process also renders it attractive. 
The inorganic hot atom chemistry can be investi-
gated with many different chemical compounds and 
different isotopes. In fact, a number of target samples 
including compounds of gold, copper, etc. have been 
prepared and a great diversity of methods have been 
used in our laboratory. This paper describes 186Re en-
richment with the inorganic Szilard-Chalmers process. 
Experimental 
Mater ia ls 
Rhenium metal powders (325 mesh, 99.997% metals 
basis, Johnson & Matthey), Rhenium(III) chloride 
(F.W. 292.56, dark red powder, 99.9% metals basis, 
Johnson & Matthey), Rhenium(V) chloride (F.W. 
363.47, dark green powder, 99.9% metals basis, John-
son & Matthey), Rhenium(VII) oxide (light yellow 
powder, F.W. 484.40, 99.99% metals basis, Johnson & 
Matthey), Rhenium silicide (ReSi2, F.W. 242.37, - 8 0 
mesh powder, 99.9% metals basis, Johnson & Matt-
hey), Rhenium(VI) oxide (ReOs, F.W. 236.20, purplish 
red powder, Johnson & Matthey), Rhenium(IV) oxide 
(Re02, F.W. 218.24, black powder, 99.9% metals 
basis, Johnson & Matthey), Rhenium foil (0.25 mm 
thick, 99.98%, F.W. 186.20, Aldrich Chemical). Rhe-
nium(VII) sulfide, (Re 60.6%, Re2S7 · H20, F.W. 
614.87, black powder, Johnson & Matthey), Acetone 
(2-propanone, >99.5%, Fisher), Magnesium chloride 
(MgCl2 · 6 H20, Mallinckrodt), Sodium hydroxide 
solution (4.95-5.05 N, standard solution, Fisher), 
Tin(II) chloride (Stannous chloride SnCl2, F.W. 
189.60, 99.99+%, Aldrich Chemical), Titanium(IV) 
chloride (TiCl4, F.W. 189.71, liquid, 99.8% metals 
basis, Johnson & Matthey). 
Target prepara t ion 
Rhenium metal film 
About 0.1 — 1 mg of Rhenium Trioxide or Rhenium 
Pentoxide were weighed in a high purity quartz tube 
with one end sealed. The open end of this quartz tube 
containing rhenium chloride was inserted into a Teflon 
tube which was connected to a vacuum pump. A car-
bon capsule (Gelman Sciences, containing activated 
charcoal particles) was installed in the vacuum line to 
trap the volatile rhenium chlorides, water and other 
chemicals that may potentially be collected into the 
system. After the vacuum pump was turned on for sev-
eral minutes, the quartz tube was placed on the flame 
of a Bunsen burner, and a thin layer of shiny metal 
film was soon produced on the quartz wall. The quartz 
tube coated with a thin layer of silvery rhenium metal 
was then rinsed with water and acetone (to remove the 
residual rhenium chloride and soluble perrhenate) and 
vacuum dried. The tube was then sealed with or with-
out vacuum using a torch. 
Rhenium and titanium oxides 
About 1—5 mg of Rhenium Trichloride or Rhenium 
Pentachloride were placed in a dry reaction vial con-
taining a magnetic stir bar. In the fume hood, 0.5 ml 
of TiCl4 (colorless liquid form, fuming and volatile) 
was added into the vial by pipette. The Re chloride 
dissolved with stirring in the TiCLt and the solution 
turned to a purple color. About 10 ml of Na2C03 
(mixed with 0.5 Ν NaOH) solution with pH > 10 was 
slowly added into the TiCL, solution; white fumes 
(presumably HCl) were released from the solution, and 
a precipitate of mixed hydrous Ti02 and Re02/Re03 
was immediately observed. The precipitate was sepa-
rated from the supernatant through centrifugation, 
washed with de-ionized water and acetone, dried with 
nitrogen gas, and stored in a desiccator. 
Rhenium and tin oxides 
About 1 mg of Re207 was dissolved in 2—3 ml of 
water and to this solution was added 2—3 ml of stan-
nous chloride solution containing about 2—3 mg of 
SnCl2. The solution was stirred and heated to ~90°C 
for 20 minutes and the dark mixture of Re(IV) and 
Tin(IV) oxides were formed. The solid precipitate was 
then collected in a clean test tube after separation from 
the supernatant, washed with water and acetone, dried 
with nitrogen gas, and stored in a desiccator. 
Rhenium and magnesium oxides 
To a sodium carbonate buffer solution at pH = —11, 
solutions of ReCl3 in acetone and MgCl2 in water were 
slowly added through two pipettes. Vigorous stirring 
was maintained during the addition of the solutions 
and the formation of purple-colored colloidal Re and 
Mg oxides. The ratio of Re/Mg was normally kept 
1:10. 
1. Irradiation of Re targets 
The rhenium targets were irradiated at 4—8X1013 
thermal neutrons/cm2/s for times varying from 10 min-
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utes to 15 hours. For irradiation times < 1 hour, 
samples were placed in high purity polyethylene vials 
and sealed at 1 atm. These vials were then placed in 
a polypropylene capsule which was inserted into the 
reflector positions through a pneumatic tube system. 
For irradiation times > 1 hour, samples were sealed 
in high purity quartz vials which were then encapsu-
lated in aluminum capsules/cans. 
Irradiations using flooded aluminum cans were 
also performed to minimize the excessive heating dur-
ing the neutron bombardment. Quartz vials were in 
direct contact with cooling water circulating through 
the holes on the aluminum wall. The temperature of 
quartz vials in flooded irradiation cans was maintained 
lower than 100°C, typically around 70 °C. 
2. Recovery of 186Re and ,88Re 
The irradiated rhenium targets were allowed to decay 
for 1 to 12 hours to minimize short-lived by-product 
radionuclides. The irradiation capsule (quartz am-
poule or polyethylene vial) was then opened using a 
vial breaker or a razor. De-ionized water or organic 
solvents such as acetone and absolute ethanol were 
added to the rhenium target and the suspension mixed 
using a vortex device. After one or two minutes, the 
supernatant was separated from solid target by fil-
tration. The radioactivity in the solvent and radioactiv-
ity remaining in the target and filter were measured 
using an AtomLab Dose Calibrator adjusted to the 
,88Re setting. Aliquots of supernatant were taken and 
analyzed with a high resolution, high purity intrinsic 
Ge detector. 
3. Determination of enrichment factors 
A fraction of supernatant containing 186Re and l88Re 
obtained from the above procedure was then trans-
ferred into a clean polyethylene vial, and the solvent 
in the vial was carefully taken to dryness under a heat 
lamp. The vial was then heat sealed and the radioactiv-
ity of 186Re and ,88Re was measured with a Ge detector 
and recorded as A,. A, was decay corrected to EOI of 
the first irradiation as A01. After most of the activity 
in the vial decayed away, the vial was irradiated at the 
same position for the same exposure time as the first 
irradiation. 
The radioactivity produced from the second ir-
radiation was then measured with a Ge detector and 
recorded as A2. After A2 was converted to A02 (the 
activity of EOI of second irradiation), A02 was com-
pared with AQ, and the enrichment factor is calculated 
as follows: 
Enrichment factor = 
A0, at EOI(I) 
A02 at EOI(II) 
same number of cold rhenium atoms in the recovered 
sample to produce the same amount of activity. On 
the other hand, if A 0 2<A 0 1 , there is less cold rhenium 
(carrier) to be activated to radioactive rhenium iso-
topes, hence the specific activity of radioactive rhe-
nium is enhanced, and thus there is a radioisotope 
enrichment. 
Results and discussion 
Rhenium metal targets 
Thus far, Re metal targets including Re metal powder 
and Re metal film (coated inside of the quartz 
ampoule) have been evaluated for irradiation at 
4 Χ 10'3 n/cm2/s (or higher) from 60 seconds up to 
three hours. Results from some experiments are shown 
below: 
Experiment 1 Re metal film freshly prepared by 
Irradiation: 
Activity: 
Enrichment: 
Experiment 2 
Irradiation: 
Activity: 
Enrichment: 
heat decomposition of ReCI, in 
quartz vial, vial was sealed at 1 atm. 
1 hour at 3 Χ 1013 n/cm2/s 
43.7% of total activity was recov-
ered in water (assayed with Atom-
Lab Dose Calibrator with l88Re 
setting). 
l86Re: 1.76 ,88Re: 2.46 
Re metal film made from ReCl, 
(heat decomposition) target was 
aged for 48 hours in an evacuated 
container. High purity quartz vial, 
sealed under vacuum (100 Torr). 
1 hour at 4ΧΙΟ ' 3 n/cm2/s 
20% of radioactivity as ,88Re was 
recovered in water 
,86Re: 3.65 188Re: 3.00 
Experiment 3 Re metal film made from ReCl3 
(heat decomposition), target was 
aged for 48 hours in desiccator. 
High purity quartz vial, sealed at 
1 atm. 
1 hour at 4X 1013 n/cm2/s 
34.3% of activity as 188Re was re-
covered in water 
186Re: 2.06 ,88Re: 2.09 
Irradiation: 
Activity: 
Enrichment: 
Experiment 4 
If the second irradiation produces the same amount of 
activity as the first irradiation, that is, A02 = A 0„ there 
is no radioisotope enrichment, since it requires the 
Irradiation: 
Activity: 
Enrichment: 
Re metal film made from ReCl, 
(heat decomposition), target was 
aged for four weeks in a desiccator. 
High purity quartz vial, sealed under 
vacuum. Irradiation using flooded 
aluminum can 
2 hours at 8 Χ 1013 n/cm2/s 
15.08% of activity as 18SRe was re-
covered in water 
,86Re: 3.24 ,88Re: 3.17 
Based on the various experiments, our obser-
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vations are (1) the use of rhenium metal (powder or 
thin film) as target materials in this type of Szilard-
Chalmers reaction produced enhanced specific activity 
of I86Re and ,88Re; (2) freshly prepared rhenium metal 
films are not suitable for irradiation because the ir-
radiated targets tend to dissolve in water; (3) it is nec-
essary to apply a vacuum in encapsulating rhenium 
metal films in the quartz ampoules; (4) irradiation with 
reduced temperature by water cooling may result in 
better and more consistent enrichment factors. It was 
originally thought that fresh rhenium targets were 
needed to minimize the formation of an oxide layer on 
the metal surface, which would possibly reduce radio-
activity recovered in water. It also appeared likely that 
we should allow air/oxygen contained in the ir-
radiation samples (in the quartz ampoules) to promote 
the oxidation of Re hot atoms. However, these con-
siderations appear to have been mistaken. The aged 
rhenium targets prepared under vacuum appeared to 
be more stable upon irradiation and resulted in higher 
radioisotope enrichment factors. This observation is 
not fully understood. Perhaps the oxygen under neu-
tron activation conditions reacted with target non-
specifically. There are a number of factors involved in 
the Szilard-Chalmers reaction that determine the 
radioisotope enrichment, among them the thickness of 
rhenium film (or the particle size of metal powder), 
oxygen level, neutron flux, reactor exposure time, tem-
perature during the irradiation, gamma irradiation, 
decay time after the irradiation, and the separation 
method for the recovery of "hot atoms". While there 
is limited room for adjustment on irradiation and sepa-
ration conditions, optimizing the preparation of ir-
radiation targets seems to be the key for achieving 
high radioisotope enrichment factors. 
C a l c u l a t i o n of the th i ckness 
of Re meta l f i lm 
A rhenium target (metal film, area of about 1 cm 
X 0.5 cm = 0.5 cm2) was coated on the quartz wall 
and encapsulated in the high purity quartz vial. This 
target was irradiated for 60 minutes. Thermal neutron 
flux-used was 4X101 3 n/cm2/s. Radioactivities of 
target at EOI: lti6Re 22.0 μΟί; and 188Re 97.6 μΟ. 
Thus, calculated mass of rhenium metal present in the 
target based on the activity, irradiation time and flux 
is —0.015 mg or 15 μg. Since the density of rhenium 
metal is 20.53 g/cm3 = 20530 mg/cm3, and area of 
rhenium film estimated is 0.5 cm2, the thickness of 
rhenium film should be 1.5 Χ 10"6 cm, or 150 A (Ang-
stroms). As the atomic radius of Re is 1.28 A, diameter 
is 2.56 A, therefore, this 150 Angstroms thickness rep-
resents —59 Re atoms. 
Rhenium oxide targets 
Various mixed rhenium oxides have been purchased 
(from Johnson and Matthey) or prepared; they are 
listed with their physical appearance in Table 1. 
Table 1. Mixed rhenium and other metal oxides 
Re Proposed Physical 
compounds formula appearance 
Re dioxide Re02 powder, black 
Re trioxide ReO, powder, dark red 
Re-Mg oxides ReO, · χ H 2 0-Mg0 powder, purple 
•yH2o 
Re-Τί oxides ReO, · χ H20-TI02 powder, green 
•YH2o 
Re-Sn oxides Re02 · χ H20-Sn02 powder, brown 
•YH 2 0 
Re sulfide Re2S7 · H 2 0 powder, dark brown 
Re silicide ReSi2 powder, black 
Re02 and Re03 
No significant radioactivities were recovered in water 
due to the relatively large particle sizes (100—200 
mesh). 
Re-Mg and Re-Ti oxides 
The results of the experiment using this preparation 
are summarized in Table 2. 
Five different rhenium mixed oxide samples were 
prepared and irradiated at 4 X 10" n/cm2/s for 60 sec-
onds. Experimental results are shown in Tables 3, 
4, 5. 
Re-Sn oxides 
About 1 mg of Re02/Sn02 (1:1 ratio) mixture was ir-
radiated at a thermal neutron flux of 4 Χ 1013 n/cm2/s 
for 30 minutes. The irradiated sample was washed 
with 5 ml deionized water and 23.3% of the activity 
was collected in the water. Enrichment factors ob-
tained from the second irradiation of the water sample 
were: 2.09 for ,86Re; and 2.00 for 188Re. 
Re2S7 • H20 
Results are summarized as follows: 
Experiment 1 
Target: 
Irradiation: 
Activity: 
Recovery: 
Solvent: 
Enrichment: 
Experiment 2 
Target: 
Irradiation: 
Activity: 
Recovery: 
Solvent: 
Enrichment: 
0.95 mg of Re2S7 · H 2 0 
4X 10'3 n/cm2/s for 10 minutes 
495 μΟί assayed with AtomLab 
Dose Calibrator 
12.4% 
de-ionized water, 5 ml 
186Re 4.06 ,88Re 3.88 
1 mg of Re2S7 · H 2 0 
4 Χ 1013 n/cm2/s for 20 minutes 
—1 mCi assayed with AtomLab 
Dose Calibrator 
41.8% 
acetone, 5 ml 
,86Re 1.48 ,88Re 1.88 
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Table 2. Szilard-Chalmers experiment (Re-Mg oxides, 2 mg, 30 minutes irradiation) 
Sample Volume First irradiation (μα) Second irradiation (μΟ) Enrichment factors 
(μΐ) 
16Re ,88Re ,86Re ,88Re ,86Re 188Re 
I 150 45.26 224.10 10.02 71.36 4.52 3.14 
II 150 35.72 171.16 7.58 60.20 4.71 2.84 
III 150 6.91 34.03 1.79 12.45 3.86 2.73 
Table 3. Re targets used in the experiment 
Sample Mass Color Starting 
ID (mg) of samples material 
A 3.5 purple ReCl5+MgCl2 
Β 2.8 ] gray/light green ReCl3+MgCl2 
C 11 gray/light purple ReCl5+TiCl4 
D 6.9 gray ReCl3+TiCl4 
Ε 14.8 green ReCl5+Ti02 
Table 4. 188Re activity recovered in the experiment 
Sample Activity Supernatant Washed Recovery 
ID (μα) (μΟ) target (%) 
(μα) 
A 134.8 82.0 54.5 60.08 
Β 75.5 54.0 17.4 71.5 
C 72.8 56.3 23.4 77.3 
D 80.9 48.9 32.7 60.4 
Ε 28.6 4.0 25.0 14.0 
Table 5. Enrichment factor for 1S81 Re 
Sample First Second Enrichment 
ID irradiation irradiation factor 
(μΟΪ) (μα) 
A 90.78 12.04 7.54 
Β 66.25 15.63 4.23 
C 15.49 3.30 4.69 
D 9.40 2.55 3.68 
Ε 2.75 2.13 1.29 
Preparation of homogeneous mixed oxide solids 
from solution appears to be much more difficult than 
anticipated. None of the mixed oxides prepared and 
evaluated in our laboratory were ideal samples. The 
rate of precipitation for each metal oxide, Re, Mg, Sn, 
or Ti in aqueous solution is different, and thus, the 
solid oxides obtained from solution were usually 
non-homogeneous mixtures of two or more individual 
hydrous oxides, for instance, Re03 · χ H20-Mg0 
• y H20, instead of Re03-Mg0 or MgRe04. The prep-
aration of the latter compound, MgRe04, required high 
temperature and pressure. A "MgRe04" sample was 
obtained from Johnson and Matthey (a special prep-
aration upon our request), but unfortunately, this com-
pound, magnesium rhenate, was actually a perrhenate 
Re(VII) which readily dissolved in water and other 
solvents such as acetone and ethanol. 
Despite the difficulties in preparing ideal rhenium 
oxide targets, all the samples prepared using "wet 
chemistry" demonstrated high activity recovery and 
some enrichment, which render them promising mate-
rials for the Szilard-Chalmers process. 
Conclusions 
Both rhenium metal film and mixed oxides are consid-
ered potentially feasible targets for the production of 
high activity as well as high specific activity 186Re. 
The experiments using rhenium metal film and mixed 
rhenium oxides were scaled up with elevated neutron 
flux and longer exposure time (8 Χ 1013 n/cm2/s for 
two hours). It appeared that rhenium metal film 
yielded higher enrichment factors than the rhenium 
oxides. 
The key to this process seems to lie in preparing 
an appropriate inorganic rhenium target material which 
can be irradiated, leached to remove "hot", water-
soluble 186Re, and then filtered to remove the carrier 
rhenium and recover the isotopically-enriched target 
for re-use. The preparation of aged and thus chemi-
cally stable rhenium metal film is vital for the consis-
tency and reproducibility of the process. Mixed oxides 
containing Re and other metals appeared to yield high 
radioactivity (typically above 20%) in the supernatant 
and achieved significant enrichment factors ranging 
from 2 to 10. Due to the current experimental con-
ditions, optimal procedures for preparing homoge-
neously mixed rhenium and other metal (Ti, Mg, or 
Sn) oxides have not been developed, and thus, consis-
tent results in terms of recovery of radioactivity and 
radioisotopic enrichment with the same or increased 
neutron flux have not been obtained. 
In summary, the inorganic Szilard-Chalmers reac-
tion using rhenium metal film or mixed rhenium ox-
ides as target materials has the potential to provide 
significantly higher specific activities of (n,y)186Re for 
radioimmunotherapy and other nuclear medicine ap-
plications. The optimization of target preparation is the 
key to the enhancement of radioisotopic enrichment. 
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Summary 
Rhenium-188 is attractive for pre-targeted radioimmunotherapy 
because of its 17 hour half life, energetic beta emission, and 
availability from a generator. Gel-type W-188/Re-188 radio-
isotope generators utilize low specific activity W-188 (half-life 
69.4 d) to produce compact isotope sources with conventional 
characteristics, thus expanding the number of reactors able to 
supply W-188 for radiotherapy. A simple "one pot" peroxide 
process has been described previously for this system [1], Now 
the effects of gel stoichiometry, boiling rate, and gel digestion 
on generator parameters of yield, breakthrough, and elution rate 
have been determined. Optimum conditions give Re-188 yields 
of 60-80% and W-188 breakthrough values of ~ 1 X 10"%/ml 
after the generator has been eluted 5 — 10 times. This Re-188 
yield is comparable to that of Tc-99m from a Mo-99/Tc-99m 
generator made by this process. The most important factor for 
minimizing breakthrough is gel stoichiometry, which is easily 
controlled in the peroxide process, while boiling rate mainly 
affects yields and ease of column elution. 
Introduction 
In the last decade there has been a renewal of interest 
in therapeutic nuclear medicine, i.e., radiotherapy with 
internal, unsealed sources for malignancies, rheuma-
toid arthritis, and certain other human maladies [2—3], 
Successful therapy depends upon matching the radio-
nuclide with the chemistry and biological kinetics of a 
carrier molecule, and a variety of radionuclides have 
shown promise in clinical trials. One particularly 
attractive radionuclide is Re-188, which exhibits a 
17 hour half life, chemical similarity to Tc-99m, 
2.12 MeV beta emission, and low abundance, im-
ageable gamma ray (155 keV, 15%). 
Furthermore, Re-188 is available in no-carrier-
added form from a W-188/Re-188 generator. Unfortu-
nately, however, W-188 is produced by double neutron 
capture from W-186, and thus is only available in low 
specific activity. A great deal of work has been done 
to use W-188 from the highest flux reactor in the U.S., 
the High Flux Isotope Reactor (HFIR) at Oak Ridge 
National Laboratory, in adsorption-type alumina col-
* Presented at the Symposium on Radiochemistry and Ra-
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umns, with some success [4], The problem with this 
approach has been that even with W-188 from HFIR, 
relatively large volume columns are needed, and the 
eluate must then be concentrated for use. 
An alternative approach has been taken at the Uni-
versity of Missouri Research Reactor (MURR) to pro-
duce W-188/Re-188 generators using a column pack-
ing of zirconium tungstate gel made from the target 
tungsten itself, from which Re-188 freely diffuses out 
in saline eluate as perrhenate [5]. This permits gram 
quantities of tungsten to be securely loaded onto col-
umns with a volume of only a few milliliters, thus 
giving 60-70% yields of Re-188 in only 1 - 3 ml of 
eluate and removing the need to concentrate the prod-
uct. This process has been refined into a "one-pot" 
peroxide method that is simple, reproducible, and con-
venient [1]. This work reports a study of the effect of 
various preparation parameters on the performance of 
the resulting generators. 
Materials and methods 
Samples of 99.7% isotopically enriched, W-186 tung-
sten metal, sodium tungstate, or tungsten trioxide were 
dried and encapsulated in quartz vials for irradiation 
in the MURR flux trap for 1—4 months at a thermal 
flux of 3 Χ1014 neutrons/cm2/sec. Samples were pro-
cessed in a glove box as previously described [1] using 
reagent grade chemicals. The finished gels were load-
ed into columns supplied by Mallinckrodt Medical, 
Inc., of the type used in the Ultratechnekow Tc-99m 
generator and eluted with normal saline, except as 
noted. Elution yield of Re-188 was assayed using an 
Atomlab 100 medical isotope dose calibrator, while 
column activity was assayed by comparison of the Re-
188 yield to the change in activity of the 931 keV peak 
of Re-188 on the column, which was counted from 
within shielding before and after elution using a ger-
manium detector and MCA. Tungsten-188 break-
through in the eluate was measured after a two week 
decay, also using a germanium detector system. Elu-
tion profiles were obtained by milking the columns in 
1 ml increments using tuberculin syringes. Parameters 
included the use of different heating block tempera-
tures to vary the peroxide solution boiling rate, varia-
tion of the Zr: W molar ratio, and use of different elut-
ing solutions. 
138 Q. Liang, G. J. Ehrhardt, A. R. Ketring and R. Miller 
D 
- J 
ω 
£ 
Ζ 
Ο Η Ρ 
ei 
90°C 
110°C 
130°C 
150°C 
170°C 
"T*· 
Fig. 
# ELUTION 
1. Effect of various heating mantle temperatures on Re-188 
elution yield vs. elution number. 
w Η < 
Μ 
Ο 3 PH 
δ 
Ρ 'Ζ) hJ μ 
TEMPERATURE 
Fig. 2. Effect of heating mantle temperature on elution rate of 
Re-188. 
Activity of W-188 used for generators ranged from 
10 μ α (0.37 MBq) to 20 mCi (0.74 GBq), the lower 
levels for tests of different eluting solutions, counter-
ions used to form the gel, and temperatures, while the 
larger activities were used for ascertaining W-188 
breakthrough and studying optimized generators. 
Results and discussion 
Fig. 1 shows the dependence of Re-188 elution yield 
on heating mantle temperature. As it was not con-
venient to measure the temperature of the W-188 solu-
tion itself, a metal-stem thermometer placed in a hole 
drilled in the aluminum shield/heating block beneath 
the flask was used to monitor the approximate tem-
perature of the solution. Thus, the exact solution tem-
perature of the W-188 was not known, but trends were 
apparent as the temperature was increased. In partic-
ular, it was assumed higher temperatures led to more 
rapid rates of H202 decomposition and gel formation. 
oi 
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Fig. 3. Percentage of Re-188 in first 1 and 2 ml eluates at differ-
ent heating mantle temperatures. 
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Fig. 4. Effect of various molar ratios of zirconium to tungsten 
on Re-188 elution yield vs. elution number. 
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Fig. 5. Percentage of incorporated W-188 into insoluble zir-
conium tungstate gel at various gel stoichiometries. 
As the peroxide decomposes and the zirconium tung-
state gel forms, gaseous oxygen is released and results 
in a porous precipitate. The degree of porosity seen by 
SEM depends on factors such as the rate of decompo-
sition (boiling) and the peroxide concentration. It is 
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evident from Fig. 1 that the yields are consistent with 
time, but decrease for higher heating temperatures. 
However, at the lower temperatures, there are con-
siderable fines in the gel that lower the elution rate 
and can clog the column (Fig. 2). As demonstrated in 
Fig. 3, the elution profile is superior at lower tempera-
tures. Thus, the optimum heating block temperature 
in our current system is about 130°C, a compromise 
between the best elution yield and profile, and reason-
able flow rates. 
A similar situation arises with respect to stoichi-
ometry. Fig. 4 describes the elution yield decreases 
with increasing ratio of Zr:W. However, as shown in 
Fig. 5, complete incorporation of tungsten into the gel 
requires an excess of zirconium, so that once again a 
compromise must be reached. A Zr: W molar ratio of 
1.5 to 2 is now used in our generator preparation for 
this reason. 
Fig. 6 demonstrates that various concentrations of 
saline eluate give basically the same yield, while de-
ionized water gives very little recovery of Re-188. 
Elution with saline/ascorbic acid and saline sodium 
citrate was not significantly different from saline alone 
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Fig. 10. Effect of various counterions on Re-188 elution yield 
of W-188/Re-188 generators. 
(Fig. 7). Elution with saline/ascorbic acid (Fig. 8) 
markedly reduced the yield of Tc-99m. This discrep-
ancy is likely the result of reduction of Tc-99m by 
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tungsten activity. Breakthrough values of about 1 ppm/ 
ml eluate, decreasing consistently over time, are char-
acteristic of these gel generators. 
Conclusions 
In regular production, parameters such as heating rate 
and stoichiometry can be fine-tuned to yield optimal 
generators. The preparation conditions will of neces-
sity be compromises between conflicting requirements 
of generator performance, e.g., high Re-188 yield and 
good elution rate. The striking dependence of gener-
ator performance on gel stoichiometry favors the con-
sistency of the peroxide process, in that the gel com-
ponents are mixed into a homogeneous, clear solution, 
and only precipitate to form the gel upon heating. 
Homogeneous gel generators permit gram loadings 
of tungsten onto small columns, thus giving very com-
pact elution profiles with no need to concentrate the 
product and with inherent protection against cata-
strophic W-188 breakthrough. Furthermore, this gener-
ator design permits useful W-188 to be produced in 
numerous intermediate flux reactors, and thus reduces 
dependence on the handful of extremely high flux re-
actors that operate in the world. This consideration in 
particular is a vital one for any industrial interest in 
producing W-188/Re-188 generators. 
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Fig. 12. W-188 breakthrough vs. time (days) from an improved 
gel W-188/Re-188 generator (14 mCi). 
ascorbate to an insoluble, reduced hydrolyzed form 
such as Tc02; perrhenate, being harder to reduce, does 
not exhibit this behavior. Fig. 9 shows the result of 
elution of identical gels with various organic eluants, 
suggesting again that saline is the optimal eluate of 
those tested. 
A variety of counterions were used to evaluate 
alternatives to zirconium, with the dependence of elu-
tion yield versus cation shown in Fig. 10. It is readily 
evident that Hf provides similar elution yields to Zr. 
However, W-188 breakthrough from a hafnium tung-
state gel is considerably greater than that from a zir-
conium tungstate gel (Fig. 11). Fig. 12 shows the time 
dependence of W-188 breakthrough from a zirconium 
tungstate gel. In Fig. 12, the amount of tungsten on the 
column was about 1 gram, so that breakthrough 
rapidly decreases to less than 10"4% of the column 
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Summary 
An improved generator was developed using a silica-based ex-
traction chromatographic resin, Eichrom Silica Actinide Resin 
(Eichrom, Danen, IL), for the production of the α-emitting ra-
dionuclide 2,3Bi and to minimize radiolysis of the 225Ac/213Bi 
generator. Ac-225 was adsorbed and evenly distributed on the 
top two-thirds of the generator resin. Bi-213 was eluted quantita-
tively with 1.0 Μ HCl. Simultaneous elution of the generator, 
subsequent dilution and re-adsorption of 213Bi onto an MP-50 
column to concentrate the activity was performed by assembling 
the columns in series. Breakthrough of 225Ac from the generator 
was <0.05%, and no 225Ac was found when 213Bi was eluted 
from the second column. Bi-213 obtained can be easily used to 
radiolabel appropriate protein chelating agent conjugates. Hypo-
thetically, resin damage by α-radiolysis should be obviated by 
employing such a silica-based resin and by broad distribution of 
the 225Ac on the column. 
Introduction 
The α-emitting radionuclides chelated to tumor-spec-
ific monoclonal antibodies can yield a high degree of 
tumoricidal activity yet spare the surrounding normal 
tissue [1,2], due to their short penetration range (40— 
100 μπι) and high linear energy transfer (LET) in tis-
sue. The use of α-emitters in systemic radio-
immunotherapy has been postulated as the treatment 
of choice for leukemia and highly vascularized tumors 
[3], and when administered intra-abdominally, as a po-
tential useful tool for treatment of intraperitoneal ma-
lignancies and micro-metastases [2]. 
In recent years, 2l2Bi (TU2 = 60.6 min) has been 
considered to be the α-emitter of choice [3], This iso-
tope can be routinely obtained from a ^ R a / ^ B i gen-
erator [4, 5]. When linked to a tumor specific mono-
clonal antibody through the bifunctional chelating 
agent p-SCN-Bz-CHX-DTPA developed in this lab-
oratory, 212Bi has been successfully used for radio-
immunotherapy studies of leukemic mice [6]. Efforts 
are currently underway to transfer this system to hu-
man clinical trials. One disadvantage, however, of 
212Bi is the shielding requirements that arise from the 
2.26 MeV y-ray of the 212Bi daughter, 208T1. For this 
reason, a hot cell of substantial dimensions is needed 
* Presented at the Symposium on Radiochemistry and Radio-
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for the safe preparation of radioimmunoconjugate 
patient doses. 
Another α-emitting bismuth isotope, 213Bi (Tu2 = 
45.6 min) has recently been promoted as an alternative 
to 212Bi [7 — 10]. Bi-213 has far fewer intense y-ray 
emissions than does 212Bi. Additionally, 213Bi emits a 
440 keV y-ray which may generate images comparable 
to that of 131I, potentially providing simultaneously 
therapy and imaging. The advantage gained due to 
simpler shielding requirements, however, is somewhat 
compromised by the yet shorter half-life. 
Bi-213 is available through an 225Ac/2,3Bi gener-
ator [7—9]. We had prepared this generator initially 
employing cation-exchange resin MP-50 previously 
used for the 224Ra/212Bi generator [10], However, this 
generator failed to function after a few days when larg-
er amounts of 225Ac were loaded onto the generator, 
such as 74 MBq (20 mCi), due to visible radiolysis of 
the resin. 
In order to minimize radiation damage to the sup-
port, we investigated the use of a silica-based extrac-
tion chromatographic resin, developed for use with ac-
tinides, for the development of 225Ac/213Bi generator in 
the current studies. 
Experimental 
M a t e r i a l s 
Ultrapure hydrochloric and nitric acids were obtained 
from J. T. Baker. MP-50 cation-exchange resin (100-
200 mesh, H+ form) was purchased from BioRad. 
Eichrom Silica Actinide Resin (Ac-Resin) and Ln-spec 
resin were obtained from Eichrom Industries, Inc. Da-
rien, IL. The bifunctional chelating agent p-SCN-Bz-
CHX-A-DTPA was synthesized, and conjugated to 
anti-Tac monoclonal antibody (Chelator: Protein = 
1.2) as previously described [11, 12], 
M e a s u r e m e n t of the r a d i o a c t i v i t i e s 
A 8192 channel multi-channel analyzer (Canberra, 
Meriden, CT) equipped with two high purity Ge detec-
tors, model GLP-16195/10 for low-energy y-ray and 
model GEM-10185 for higher-energy y-ray (EG and G 
Ortec, Oak Ridge, TN), was used for high resolution 
y-ray spectroscopy. The 225Ra and 213Bi activities were 
determinated by measurement of their 40 keV X-ray 
and 440.4 keV y-ray, respectively. To quantify the 
142 Chuanchu Wu, Martin W. Brechbiel and Otto A. Gansow 
225Ac activity, the intensity of the 218 keV γ-ray of its 
221Fr daughter nuclide (Tu2 = 4.8 min) was measured 
at secular equilibrium with the parent. 
Separat ion of 225Ac f rom 225Ra 
Ac-225 was supplied by Pacific Northwest National 
Laboratory, Richland, WA, as the mixture with 225Ra. 
The 225Ra was removed by column extraction chroma-
tography with Ln-Spec resin. Briefly, the mixture of 
225Ra and 225Ac in 0.1 Μ HN03 was loaded onto a col-
umn of Ln-Spec resin (4 X 20 mm). After 225Ra was 
eluted from the resin with 0.1 Μ HN03, the 225Ac was 
eluted with 0.5 Μ HN03. 
De te rmina t ion of weight d is t r ibut ion 
coe f f i c i ency of Ac-Resin 
The sorption of 225Ac(III) and 213Bi(III) from HCl solu-
tion by the Ac-Resin was measured by contacting 
2.0 ml of a spiked acid solution of appropriate concen-
tration with a known weight of the resin (50—100 mg). 
The mixing of the solid and liquid phases was per-
formed by gently shaking for 30 min at 25 °C. After 
equilibrium, the resin was removed by filtration 
through Whatman # 1 paper. 
Weight distribution coefficiencies were calculated 
from the following equation: 
_ (A0 - As)/W 
As/V 
where A0 and As are the aqueous phase activities before 
and after equilibration, respectively, and W is the 
weight of resin (g) and V is the aqueous phase volume 
(ml). 
Prepara t ion of the 225Ac/213Bi genera tor 
A column (8X2 mm) was packed with Ac-Resin 
(1 ml) and the resin equilibrated with 0.5 Μ HN03. 
About two-thirds of the resin was removed from the 
column, and added to a test-tube containing 2.96 MBq 
(0.8 mCi) 225Ac in 0.5 Μ HN03 (2 ml). The mixture 
was incubated at room temperature for 30 min with 
occasional shaking. The resin was then returned to the 
column, and equilibrated with 1.0 Μ HCl. All of the 
solutions were collected, and assayed for 225Ac ac-
tivity. 
Elut ion of the 225Ac/213Bi genera tor 
Bi-213 was eluted from the 225Ac/213Bi generator with 
1.0 Μ HCl, and then concentrated with a second col-
umn of MP-50 resin. A specially designed system 
(Fig. 1) was used to performe the operation. 
The system contains two peristaltic pumps (Pharm-
acia, Sweden). From the first pump, 1.0 Μ HCl was 
From Pump #1 From Pump #2 
1.0 Μ HCl H20 1.0 ml / min 4.0 ml / min 
Fig. 1. The 225Ac/211Bi generator elution system. 
delivered at 1.0 ml/min to the ^Ac/^ 'Bi generator to 
elute the 213Bi. The HCl solution was then mixed with 
H20 delivered by the second pump at 4.0 ml/min. The 
resulting diluted eluate ([HCl] = 0.2 Μ) was then 
passed through the column of MP-50 resin 
(5 X 1.5 mm). After 6 min, the MP-50 column was dis-
connected from the system, and 213Bi was eluted from 
this column with 0.5 ml of 0.1 Μ HI delivered via syr-
inge. 
The generator was eluted twice a day ( 3 - 5 hours 
apart) on weekdays for two weeks. The yield of 213Bi 
and the 225Ac breakthrough after the generator and the 
MP-50 column were determined. 
Radiolabel ing of mAb conjuga tes 
Radiolabeling was performed by adjusting the pH of 
213Bi in 0.1 Μ HI with 3.0 Μ NH,OAc to 5.0-5.5. The 
anti-Tac-CHX-A-DTPA was added to the solution, and 
after 6 min incubation at room temperature, 5 μΐ of 
0.1 Μ EDTA were added. The radiolabeled antibody 
was purified with a size-exclusion HPLC column TSK 
3000SW (TosoHaas, Japan, elute with PBS at 1.0 ml/ 
min). 
Results and discussion 
The 225Ac can be separated from 225Ra with Dowex 
50W-X8 cation exchange resin [13, 14], however, this 
chromatography is inconveniently performed at 60 °C 
or 80°C. Also, we found the yield of 225Ac by this 
method to be relatively poor. In this study we explored 
the potential for use of the extraction chromatographic 
resin, Ln-spec, to separate these two isotopes. The Ln-
spec resin uses a polymeric support, Amberlite XAD-
7 beads, impregnated with extractant bis(2-ethyl-
hexyl)phosphoric acid (HDEHP). The Ac-Resin em-
ploys silica beads impregnated with the extractant 
di-2-ethylhexyl-methylene-bis-phosphonic acid. This 
separation of the isotopes was performed at room tem-
perature, and yielded quantitative recovery for 225Ac. 
The acid dependency of weight distribution coef-
ficiency Dw of the Ac-Resin for trace amounts of 
Ac(III) and Bi(III) is shown in Fig. 2. Ac(III) was re-
tained very strongly by the resin over a wide range of 
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[HCl], Μ 
Fig. 2. Acid dependency of weight distribution coefficiency of 
silica Ac-Resin for 225Ac(III) and 213Bi(III) at 25 °C. 
HCl concentration. The resin also showed high affinity 
for Bi(III) at low acid concentration, but the distri-
bution coefficient sharply decreased with increasing 
HCl concentration. We chose 1.0 Μ HCl as the gener-
ator eluent, wherein the weight distribution coef-
ficiency of the Ac-Resin for Ac(III) is greater than 105, 
while approximately unity for Bi(III). 
If 225Ac was loaded onto the column by simply 
passing the solution through the column 225Ac was ad-
sorbed on a very thin layer of resin at the top of the 
generator due to the extremely strong affinity of the 
Ac-Resin for Ac(III). The radioactivity density then 
would be great regardless of column size, and conse-
quently, this portion of the resin bed suffers radiolysis 
damage. Our technique of packing the column de-
scribed herein obviates this deleterious effect by even-
ly distributing the 225Ac over the upper two-thirds of 
the column. Before re-packed to the column, the Ac-
Resin retained >99% of 225Ac, confirmed by counting 
10 12 14 16 18 20 
Time (Min.) 
Fig. 4. The decay curves of 213Bi and a mixture of 221Fr/2l1Bi 
with equal amount at t = 0. 
the aqueous aliquot. The remaining resin then is in 
place to eliminate 225Ac breakthrough during the prep-
aration and the elution of the generator. Less than 
0.5% of the total 225Ac was found in the solution col-
lected during the preparation of the generator. 
Five column volumes were required to completely 
(>96%) elute 213Bi from the generator (Fig. 3). To in-
sure maximum yield of 213Bi, six column volumes of 
1.0 Μ HCl were used to elute the generator. However, 
this leaves the activity in 6 ml (for a 1 ml generator), 
too large a volume for practical radiolabeling of anti-
body conjugates. Additionally, we have proposed to 
employ even larger generators with clinically useful 
amounts of 225Ac, to decrease the resin radiation den-
sity to minimize radiolysis. Therefore, the 213Bi solu-
tion must be concentrated for further use and for radio-
labeling protein conjugates. This was easily done by 
directly loading the dilute 213Bi solution onto a MP-50 
cation exchange column. 
The optimal acid concentration to retain the 213Bi 
on MP-50 resin was found to be 0.2 Μ HCl, thus, a 
so.o 
40.0 
Ό 
α> 3o.o 
LU ÖQ 20-0 
10.0 
0.0 
41.1% 
35.7% 
- -
11.5% 
- 8.1% -
0% 
1.3% 0.8% 0.6% o.2% 0.2% 
3 4 5 6 7 
Fraction Number 
9 10 
Fig. 3. Elution profile of 213Bi from the 225Ac/213Bi generator with 1.0 Μ HCl. Each fraction contains 1.0 ml eluent. Column size: 
8X20 mm, 1 ml). 
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5-fold dilution was required. Under these conditions, 
greater than 95% of the 213Bi activity from the gener-
ator was retained by the MP-50 column when the solu-
tion was passed through the MP-50 column at 5 ml/ 
min. If the eluate from the generator was diluted to 
0.1 Μ or 0.3 Μ HCl, 8% and 11% of the 213Bi was not 
retained on the MP50 column, respectively. 
The decay loss of 213Bi during the elution is mini-
mal for two reasons. First, elution of the generator and 
the subsequent concentration were performed as a 
continuous flow process and the loss of 213Bi by decay 
during this process would be replaced in part by the 
growth of 213Bi in the generator. Secondly, the decay 
of the short-lived parent, 221Fr (TU2 = 4.8 min), that 
was also eluted from the generator and then also re-
tained by the MP-50 resin, produces 213Bi by decay. 
As seen in Fig. 4, almost 10% of 213Bi will be decayed 
after 6 min from a pure 213Bi source and only 3% is 
effectively decayed for a mixture of equal amounts of 
221Fr and 213Bi. 
The overall yield of 2,3Bi from our generator sys-
tem is greater than 85% without decay correction. 
Breakthrough of 225Ac from the column of the gener-
ator is <0.05% after greater than 20 elutions and no 
225Ac was observed after 213Bi was concentrated 
through the MP-50 column. 
The chemical purity of the 213Bi final product was 
high, confirmed by its easy labeling of anti-Tac conju-
gated with CHX-A-DTPA. Typical radiolabeled pro-
tein product specific activities ranged from 37—74 
MBq/mg (10—20 mCi/mg) as calculated after purifica-
tion. 
Although the packing technique described herein 
could be applied to MP-50 resin employed for the 
224Ra/212Bi generator, we were unable to develop an 
efficient method to concentrate 213Bi in an HI solution 
within acceptable time limits. If HCl (0.5 Μ minimum 
for elution of Bi from MP50) was used, measurable 
225Ac breakthrough began after ~ 1 0 column volume 
elutions. 
In conclusion, the new generator employed a sili-
ca-based extraction chromatographic resin, Ac-Resin, 
retained 225Ac very tightly, while 213Bi could be readily 
eluted with 1.0 Μ HCl. The 225Ac was evenly distrib-
uted in the upper two-thirds of the generator column, 
which was expected to distribute and decrease the 
radiation density. Addition of a concentration step 
after generator elution not only eliminated possible 
225Ac breakthrough, but also potentially allowed in-
crease the generator column size to further decrease 
radiation density. The new generator design for elimi-
nating radiolysis damage continues to be investigated 
pending availability of 225Ac (>74 MBq). 
Acknowledgments 
Thanks are due to Dr. Robert Shenter and Dr. Lane 
Bray (Pacific Northwest National Laboratory) who 
supplied the 225Ac activity. 
References 
1. Humra, J. L., Chin, L. M.: A Model of Cell Inactivation 
by Alpha-Particle Internal Emitters. Radiat. Res. 134, 143 
(1993). 
2. Macklis, R. M., Kinsey, Β. M., Kassis, A. I., Ferrara, J. L. 
M., Atcher, R. W., Hines, J. J., Coleman, C. N., Adelstein, 
S. J., Burakoff, S. J.: Radioimmunotherapy with Alpha-
Particle-Emitting Immunoconjugates. Science 240, 1024 
(1988). 
3. Wilbur, S.: Potential use of α-emitting Radionuclides in the 
Treatment of Cancer. Antibody, Immunoconj. Radiopharm. 
4, 85 (1991). 
4. Atcher, R. W., Hines, J. J., Friedman, A. M.: A Remote 
System for the Separation of 228Th and 224Ra. J. Radioanal. 
Nucl. Chem. Lett. 117, 155 (1987). 
5. Atcher, R. W., Friedman, A. M., Hines, J. J.: An Improved 
Generator for the Production of 2,2Pb and 2,2Bi from 224Ra. 
Appl. Radiat. Isot. 39, 283 (1988). 
6. Huneke, R. B., Pippin, C. G., Squire, R. Α., Brechbiel, Μ. 
W., Gansow, Ο. Α., Strand, Μ.: Effective α-Particle-me-
diated Radioimmunotherapy of Murine Leukemia. Cancer 
Res. 52, 5818 (1992). 
7. Geerlings, M. W.: Radionuclides for Radioimmunotherapy: 
Criteria for Selection. Intl. J. Biol. Markers 8, 180 (1993). 
8. Geerlings, M. W., Kaspersen, F. M., Apostolidis, C., Van 
Der Hout, R.: The Feasibility of Ac-225 as a Source of a-
Particles in Radioimmunotherapy. Nucl. Med. Commun. 14, 
121 (1993). 
9. Geerlings, M. W.: Radioimmunotherapy Using α-Particles 
Emission. Int. Patent WO 90/15625 (1990). 
10. Pippin, C. G., Gansow, Ο. Α., Brechbiel, Μ. W„ Koch, L., 
Molinet, R., Van Geel, J., Apostolidis, C., Geerlings, M. W., 
Scheinberg, D. Α.: Recovery of Bi-213 from an Ac-225 
Cow: Application to the Radiolabeling of Antibodies with 
Bi-213. In: Chemists' Views of Imaging Centers (A. M. Em-
ran, ed.) Plenum Press, New York 1995. 
11. Brechbiel, Μ. W., Gansow, Ο. Α.: Synthesis of C-Func-
tionalized Derivatives of trans-Cyclohexyldiethyl-
enetriaminepentaacetic Acid for Labeling of Monoclonal 
Antibodies with the 212Bi Alpha-particle Emitter. J. Chem. 
Soc., Perkin Trans. 1, 1173 (1992). 
12. Mirzadeh, S., Brechbiel, Μ. W., Atcher, R. W., Gansow, O. 
A.: Radiolabeling of Immunoproteins: Covalent Linkage of 
2 - (4 - Isothiocyanatobenzyl) diethylenetriamine - pentaacetic 
Acid Ligands to Immunoglobulin. Bioconjugate Chem. 1, 
59 (1990). 
13. El Samad, O., Dalmasso, J., Barcl-Funel, G., Ardisson, G.: 
Fast radiochemical Separation and γ Spectroscopy of Short-
lived Thallium Isotopes. Radiochim. Acta 62, 65 (1993). 
14. Kouassi, M. C., Dalmasso, I., Maria, H., Ardisson, G., Hus-
sonnois, M.: On the y-Spectrum Following 225Ac α-Decay. 
J. Radioanal. Nucl. Chem. Lett. 144, 387 (1990). 
Radiochimica Acta 79, 145-149 (1997) 
© R. Oldenbourg Verlag, München 1997 
Optimizations of Radiolabeling of Immunoproteins with 213Bi * 
By Rose A. Boll, Saed Mirzadeh** and Stephen J. Kennel 
Divisions of Health Sciences Research and Biology, Oak Ridge National Laboratory, Oak Ridge, TN 37831-6226, USA 
(Received January 10, 1997; accepted in revised form May 23, 1997) 
225Ra - 225Ac - 2,3Bi / Multidentate ligands / 
CHX-b-DTPA / Alpha-particle mediated radio-
immunotherapy / Radiochemistry 
Summary 
Carrier-free 213Bi ((f1/2 = 45.6 m, an α-emitter) is available from 
the 225Ra/225Ac/213Bi generator system with 225Ra (f1/2 = 14 d) 
and 225Ac (tU2 = 10 d) being the daughters of 7340-y 229Th 
which, in turn, is the decay daughter of long-lived 233U. In the 
current generator system, 225Ra/225Ac is adsorbed on an organic 
cation exchange resin (AG 50X4, X8 or highly cross-linked AG 
MP-50) and 2,3Bi is eluted with 0.1 Μ HI. We have found the 
lower cross-linked resin to be more suitable for rapid elution 
of 2,3Bi from the generator with 225Ac breakthrough of <1%. 
Generators were typically made from Ac separated from Ra as 
the breakthrough of Ra is significantly higher than that of Ac. 
Generator elution of 213Bi, labeling of MAb and HPLC purifica-
tion were accomplished within 35—40 min. Radiolabeling yields 
of CHX-b-DTPA-conjugated MAbs (34A and 14) were >50% 
with specific activity of ~200 μ(Γί of 213Bi per 150 of conju-
gated protein. 
Introduction 
Due to their short range in tissue (a few cell diam-
eters), and high linear-energy-transfer (LET), alpha 
particles are of considerable interest for therapeutic 
applications, especially for treatment of leukemia and 
other blood borne disease [1—5]. Most recently, their 
applications with vascular targeting antibodies for 
treatment of lung cancer have been under evaluation 
[6]. The list of potential radionuclides for alpha-
particle mediated radioimmunotherpay includes only 
four «-emitting radioisotopes, namely 21'At (i1/2 — 
7.2 h) [7], 212Bi (tl/2 = 60.6 m) [8, 9], 213Bi (tv2 = 
45.6 m) and 255Fm (tu2 = 20 h) [10]. Among these pos-
sible candidates, 255Fm (the daughter of 40-d 255Es, a 
transuranium radioisotope) has the most convenient 
half-life, but it is doubtful that useful quantities of this 
radioisotope will be made available within the foresee-
able future. The availability of 211At is also very lim-
ited because there are only a few cyclotrons in the 
U. S. capable of accelerating α-particles to ~28 MeV, 
which is the required energy for production of 211At 
via the 209Bi [a,2n] reaction (the predominant produc-
tion route). Bismuth-212 is available from the 224Ra/ 
212Bi generator system, where 224Ra is the daughter of 
* Presented at the Symposium on Radiochemistry and Radio-
immunotherapy, Orlando, Florida, USA, August 1996. 
** Author for correspondence. 
1.9-y 228Th [8], The major drawback for the use of 
212Bi is emission of a relatively intense and very high 
energy "/-rays (2.6 MeV, 38%). The presence of this 
high energy y-ray is a debilitating risk to the patient, 
the patient's family members and the medical staff in-
volved in the treatment. Bismuth-213, on the other 
hand, emits a 1.5 MeV y-ray with a probability of only 
2%. Similarly, carrier-free 2l3Bi is available from the 
225Ac/213Bi generator system with 225Ac (tu2 = 10 d) 
being the daughter of 7340-y 229Th which, in turn, is 
the decay daughter of long-lived 233U. 
In this work, we evaluated a 2 mCi generator for 
213Bi yield and elution profile, and 225Ra and 225Ac 
breakthroughs. The generator was eluted 28 times dur-
ing a 18-day period. Parallel with the evaluation of the 
generator, we studied the influence of various parame-
ters on the 213Bi labeling yields of three chelate-modi-
fied monoclonal antibodies. In addition, we examined 
the potential use of extraction column chromatography 
for separation of Ac from Ra. 
Experimental 
Materials , reagents and instrumentat ion 
To reduce metal ion contamination, specifically the 
common metals [e.g. Fe(III), Zn(II), Cu(II)], plastic-
ware (metal-free low protein binding polypropylene) 
was used in almost all protein work. Chelex-100 che-
lating ion exchange resin (Na+ form, 100—200 mesh) 
and the AG 50WX4 cation resin (H+ form, 200-400 
mesh) were purchased from Bio-Rad Laboratories. 
The resins were washed with and stored under deion-
ized H20. AS needed, AG 50WX4 was converted to 
nitrate form by contacting resin with 8 Μ HN03 and 
rinsing with deionized H20. LN resin (HDEHP im-
pregnated polymers, 100-150 μπι) was obtained from 
ElChrom Industries Inc. All other reagents used were 
of analytical grade or better. In general, all buffers 
were passed through a column of Chelex-100 resin 
(2.5 X 10 cm, pre-equilibrated with the same buffer) 
and finally, prior to storage at 4° C, they were filtered 
through a 0.22 micron sterile cellulose acetate mem-
brane filtration unit (e.g. Corning 25942, Corning, 
NY). Ra/Ac-225 was from ORNL or was purchased 
from Pacific Northwest National Laboratory (PNNL). 
Monoclonal Antibodies 273-34A (34A), 411-201B 
(201B) and 135-14 (14) were prepared at ORNL [11]. 
Bifunctional chelating ligand Cyclohexyl-diethyl-
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Fig. 1. Separation of 225Ra and 225Ac by column extraction. 
Column: - 2 X 2 0 mm, - 2 5 0 μ ί of LN resin (HDEHP im-
pregnated polymers), 100—150 μηι (ElChrom Ind. Inc.); Load: 
100 μ α of 225Ac and 225Ra in 100 yL of 0.03 Μ HN03 ; Flow 
rate: —0.5 mL/min. 
2 4 6 8 10 12 
30 - μΙ_ Fractions 
2 4 6 8 10 12 
30 - μί Fractions 
Fig. 2. Elution profile of the 2,3Bi generator. Column: ~ 2 X 
15 mm, - 2 0 0 μ ι of AG50W-X4 resin, 200-400 mesh; Load: 
30 μ α 225Ac and and 1.1 μ Ο 225Ra in 100 μ ί of 1.0 Μ HN0 3 ; 
Flow rate: —0.5 mL/min. 
enetriaminepentaacetic Acid (CHX-DTPA, isomers a 
and b) was furnished by Dr. M. Brechbiel and late Dr. 
O. A. Gansow at the National Institutes of Health [12], 
Separa t ion of Ac f rom Ra and Prepara t ion 
of 225Ac/213Bi genera tor 
The generator was made from 225Ac separated from 
Ra. Separation of Ac/Ra was achieved by extraction 
column chromatography using LN resin, where the Ra/ 
225Ac mixture ( - 2 0 0 μΟ) in 0.01 Μ HN03 was loaded 
onto a 3 X 20 mm column containing ~250 μ ί of LN 
resin. The generator was then washed with 3 column 
volumes of 0.03 Μ HN03 to remove all Ra, and sub-
sequently, Ac was eluted with 0.3 Μ HN03. The 225Ac 
solution was evaporated to dryness and residue redis-
solved in 3 X 200 μ ί of 1 Μ HN03 and loaded onto a 
new column (2X1.5 mm, AG 50WX4, 200-400 
mesh in NO^ ~ form, pre-equilibrated with 1 Μ HN03). 
The generator was then washed with 200 μ ί of H20 
and allowed to stand for at least 3 hours for 213Bi ac-
tivity to reach equilibrium (~90%). Carrier-free 213Bi 
was selectively eluted from generator using 0.15 Μ 
HI, buffered to pH 3.8-4.5 with NaOAc for the sub-
sequent radiolabeling procedure. 
Prepara t ion of 2 1 3Bi-labeled ant ibody 
CHX-DTPA conjugated antibody was prepared with 
the ligand-to-protein-molar ratio of 1-2 according to 
procedure of Mirzadeh et al. [13]. The unconjugated 
or free ligand was separated from protein by serial di-
alysis (2 X 500 mL of citrate buffer for 16 hours each 
and then against 500 mL of MES buffer for a few 
hours). The final ligand to protein molar ratio, (CL/ 
P)f, of the conjugated antibody was then determined 
[14,15]. The chelate conjugated antibody was labelled 
with 213Bi as follows: buffered solution (pH 3.8-4.5) 
of 213BiI3 containing —500 μ Ο of 213Bi was mixed 
with - 1 0 μ ί of CHX-MAb ( - 1 0 mg/mL). The reac-
tion pH was raised to 5.0—5.5 by addition of μ ί ali-
quots of 3 Μ NaOAc. The reaction mixture was placed 
in a constant temperature bath for the desired period of 
time, then the reaction was quenched by adding 2 μ ί 
10 mΜ Na2EDTA to scavenge any free 213Bi. Sub-
sequently, the radiolabeled antibody was purified from 
unreacted 213Bi by HPLC employing a TSK-400 size 
exclusion column. The HPLC was operated isocraticly 
at pH = 6.2 (MES buffer) with 1.0 ml/min flow rate, 
and was equipped with dual on-line UV- and radioac-
tivity detectors. Radiolabeling yield was determined as 
the ratio of the radioactivity under protein peak to the 
total activity in all fractions. 
Results and discussion 
Results of separation of 225Ra and 225Ac by column 
extraction employing LN column are depicted in 
Fig. 1. As shown, complete separation of Ac from Ra 
can be achieved by loading the mixture on the LN 
column from 0.01 Μ HN03 followed by 3 column vol-
umes of 0.03 Μ HN03 rinse. Elution of Ac from the 
LN column can be selectively achieved by use of 
0.3 Μ HN03. Sharper elution of Ac from the LN col-
umn can be accomplished with acid of higher concen-
tration if there were no potential of contamination 
from Th. The elution profile of 213Bi from the Ac/Bi 
generator is shown in Fig. 2. In this case the load solu-
tion consisted of 830 μ Ο 225Ac and 1.1 μ Ο 225Ra in 
100 μ ί of 1.0 Μ HN03. As shown, the first column 
volume ( - 2 0 0 μ ί ) contains 95% of the 213Bi, and 
quantitative elution can be achieved by washing col-
umn with additional 60 μ ί of H20. A summary of the 
2t3Bi yield and 225Ac and 225Ra breakthrough values are 
given in Table 1. As indicated in the last column, the 
breakthrough of Ra in AG 50WX4 resin was substan-
tially higher than Ac breakthrough. Thus it follows 
that in order to reduce the potential contamination of 
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Table 1. 2 2 5Ac/^Bi generator - 213Bi yield, 225Ac and 225Ra breakthrough 
Elution Date 2,3Bi Breakthrough Ra/Ac 
No. (d) yield 
(μΟ) 225Ac 225Ra 
( μ α ) (%) ( μ α ) (%) 
1 3 650 4.3 X 10~3 6.4 Χ Ι Ο - 2.8 X10"3 2.9X10" ' 453 
6 4 615 6.7 X10"3 Ι . IX 10"3 1.2 Χ ΙΟ"3 1.3X10"' 118 
15 11 406 2.9 X10"2 7.5 X10"3 1.5 Χ 10"3 2.3X10" ' 31 
19 13 351 2 .9X10- ' 8.6 X 1 0 2 1.4 Χ ΙΟ"3 2.4X10" ' 2.8 
23 14 325 6.0X 10 2 1.9 X10"2 1.3 Χ 10"3 2 . 3 X 1 0 - 12 
28 18 218 1.3 X10"2 5.6 X 10~3 1.3 Χ ΙΟ"3 2 . 7 X 1 0 - 52 
Column: - 2 X 15 mm, - 2 0 mg of AG50W-X4 resin 
Load: 830 μΟί 225Ac and 1.1 μ α 225Ra in 100 \>L· of 0.03 Μ HN0 3 
Eluent: 200 μ ί of 0.15 Μ HI, How rate: - 0 . 5 mL/min 
Table 2. Chelate conjugations of various monoclonal antibodies 
MAb [ P F 
(mg/ml) 
Chelate CHX-
DTPA2 
(Ch/P),3 (Ch/P)f3 
273-34Α 13.9 b 5 0.5 
8.9 b 10 1.9 
8.9 b 20 2.9 
9.8 a 10 0.6 
9.3 a 10 1.4 
411-201Β 19.9 b 10 1.1 
13.3 a 10 1.3 
135-14 10.7 b 5 0.8 
11.3 b 10 1.4 
10.3 a 10 1.2 
pH: 8.6, Temperature: 22°C, Reaction time: 16 h. 
1 [P]j: Initial protein concentration. 
2 a and b refer to two isomers of CHX-DTPA, see Ref. [12]. 
3 (Ch/P); and (Ch/P)f: Initial and final chelate to protein ratio, 
respectively. 
Table 3. Radiolabeling as a function of time 
Rxn time η Radiolabeling Radioactivity 
(min) yield (%) recovery (%) 
2 1 39.4 94.2 
3 1 59.9 90.7 
5 2 79.8 ±1 .7 101 ± 2 
10 5 77.8 ± 6 . 1 95.8 ± 4 . 1 
12 1 73.9 94.3 
15 2 82.1 ± 2 . 8 94.4 ± 4 . 6 
Av. 95.1 ± 3 . 4 
Protein: CHX-b-201B, 100 μg( ch/p = 1.1 
Reaction vol.: 400 μΐ . 
Temperature: 22°C 
Reaction pH: 4 .8 -5 .0 
213Bi with Ra, the Ac generator-load solution should 
contain low fraction of Ra. 
Results of conjugations of three anti bodies 273-
34A, 411-201B and 135-14 are summarized in 
Table 2. In general, consistent with previous obser-
vation, the final chelate-to-protein ratio is a linear 
function of the initial chelate-to-protein ratio [13]. For 
Table 4. Radiolabeling as a function of temperature 
Rxn temp. η Radiolabeling Radioactivity 
(°C) yield (%) recovery (%) 
22 5 77.8 ± 6 . 1 95.8 ± 4 . 1 
30 4 81.4 ±4 .6 98.7 ± 1 . 8 
40 2 86.5 ± 1 . 9 100 ± 5 
Protein: CHX-b-201B, 100 μg, ch/p = 1.1 
Reaction vol.: 400 μ ι 
Reaction time: 10 min 
Reaction pH: 4 .8 -5 .0 
example, in the case of 34A antibody and CHX-b-
DTPA chelate, for an initial chelate-to-protein ratio of 
10, protein concentration of 8.9 mg/ml, pH of 8.6 and 
16-h incubation, the final chelate-to-protein ratio was 
1.9. Under similar conditions but (Ch/P); = 20, the 
final chelate-to-protein ratio of was 2.9. Increasing the 
(Ch/P)i above 15 resulted in aggregation of proteins 
(34A and 201B) as measured by HPLC. Results of 
radiolabeling at room temperature as a function of re-
action time is shown in Table 3. Within the first 5 min, 
the labeling yield increases rapidly to ~80% but then 
it remains rather constant. The effect of temperature 
on radiolabeling yield is shown in Table 4. For a 10-
min reaction time, the labeling yield increases only 
11% when reaction temperature increased by almost a 
factor of 2, from 22 to 40° C. 
Results of labeling as a function of protein concen-
tration are summarized in Table 5. The radiolabeling 
yield remains —75% when the concentrations of che-
lated protein [with (CL/P)f = 1.1] in the reaction mix-
ture were 125—250 μg/mL. Further decrease in con-
centration of chelated protein resulted in a decrease in 
radiolabeling yield. When the concentration of che-
lated protein was 25 μg/mL, the yield was only 22%. 
The ratio of 213Bi (μ(ϋί) incorporated per μg of protein 
also decreased from 4.5 to 1.6 as concentration of con-
jugated protein increased tenfold, from 25 to 260 μg/ 
mL (Table 5, column 5). In these experiments the total 
concentration of protein was kept constant at 250 μg/ 
mL by addition of unchelated antibody. Bi-213 occu-
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Table 5. Radiolabeling as a function of protein concentration 
Chelated η Labeling Activity 2,3Bi to Sites 
protein yield recovery protein occupied 
fog) (%) (%) foCiAig) (%) 
10 1 22.4 95.1 4.5 7 X 10~2 
25 1 35.6 94.6 2.8 2X 10 3 
50 1 74.1 94.6 3.0 4X 10~3 
75 1 73.5 93.4 2.0 5X 10 3 
100 5 77.8 ±6 .1 95.8 ±4 .1 1.6 7X 10 3 
Chelated protein: CHX-b-201B, ch7p = 1 . 1 
Reaction vol.: 400 μΐ . 
Reaction pH: 4 .8-5 .0 
21,Bi Sp. Act.: 2X107 μ Ο ί ^ 
Total protein: 100 μg 
Temperature: 22° C 
Total activity: 200 μ Ο 
Reaction time: 10 min 
pies only 0.1% of available sites on chelated antibody, 
which does not explain why quantitative labeling 
could not be achieved (Table 5, column 6). This calcu-
lation is based on the assumption that these ligands 
bond to only one 213Bi ion (a theoretical specific ac-
tivity of 2 Χ 107 mCi^g for 213Bi was used). The prob-
lem most likely lies with the presence of common 
metal ion impurities at the part per billion level in 
chemical regents. Even though great care was taken to 
eliminate these ions, certain ions a with strong affinity 
for DTPA, such as Fe(III), even at concentrations be-
low the detection limits of common analytical instru-
mentation can compete with 213Bi for the available sit-
es on the protein. The immunoreactivity of the 213Bi-
labeled 201B and 34A were preserved as indicated by 
the in vivo experiments where 50% of the total activity 
is delivered to the target organ [6], 
In support of our on-going in vivo experiments, 
over one hundred labelings have been performed using 
ten generators at levels of 1—3 mCi. Our observations 
of the radiolytic effects of 225Ac and its decay products 
on the shelf-life of the generator can be summarized 
as follows: Within a week of loading a new generator, 
a dark band appears on the top of the resin, and it 
progressively darkens. If the generator is not eluted 
regularly (at least once a day), in a few days the flow 
of liquid is totally obstructed, presumably due to repo-
lymerization of the resin's radiation-induced degra-
dation byproducts. On the contrary, the generators per-
form well, with no significant reduction in labeling 
yields, when they are regularly eluted. In a few in-
stances, reasonable labeling yields (—60%) were ob-
tained from the two-week old generators which had 
been eluted extensively (2—3 times a day). These ob-
servations are consistent with the fact that the decay 
daughters of 225Ac contribute significantly to the total 
radiation damage of the resin and by removing them 
on a regular basis the generator shelf-life can be ex-
tended. 
Bi-213 was attached to monoclonal antibodies 
using isothio-cyanatobenzyl derivatives of CHX-
DTPA chelating ligands [12] \ These chelating ligands 
contain a protein binding group that is distinct from 
the metal-chelating group. The SCN group on these 
ligands reacts with ε-amino groups, predominately on 
lysine side chains of immunoglobulins, with formation 
of a thiourea group. Systematic study of the chemical 
factors which influence binding of the SCN-Bzl-DTPA 
to protein has been reported earlier [13], A pivotal 
issue in designing an optimal radiotherapeutic reagent 
is the chemical stability of the metal chelate system. 
The complexes of Bi+3 ions with eight-coordinated 
DTPA are kinetically inert in aqueous solutions with 
the overall equilibrium constant of 4X1035 Μ 1 (at 
20° C and 0.1 Μ ionic strength, [17]). The in vivo 
stability of 212Bi-CHX-DTPA antibody (anti-Tac) has 
also been demonstrated earlier [5] and the in vivo 
stability of 213Bi labeled 34A and 201B antibodies has 
been reported by us in these proceedings [6], 
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